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Assistant Professor Simon J. Fisher, Chairperson 
 
As glucose is the main fuel source for the brain and a major nutrient for peripheral 
tissues, the brain must sense and respond to changes in blood glucose in order to sustain 
its own nutritional requirements and maintain whole body energy homeostasis.  
Disruption of brain glucose sensing results in impaired glucose tolerance, a hallmark in 
the pathogenesis of diabetes, as well as increased risk of severe hypoglycemia as occurs 
with insulin therapy.  Thus, understanding how the brain senses and responds to changes 
in glucose is particularly important to individuals with diabetes.  Experiments in this 
thesis investigated (1) the role of neuronal glucose transporter 4 (GLUT4) in glucose 
sensing and the counterregulatory response to hypoglycemia, (2) the adaptive response of 
the brain to antecedent hypoglycemia, and (3) the role of hyperglycemia and the 
hexosamine biosynthetic pathway (HBP) in the hypothalamus on regulating energy 
homeostasis.  Neuronal GLUT4 was found to play a crucial role in modulating peripheral 
insulin sensitivity and was necessary for eliciting a full counterregulatory response to 
hypoglycemia.   Antecedent moderate hypoglycemia preconditioned and protected the 
brain from neuronal injury and cognitive dysfunction induced by an episode of severe 
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hypoglycemia.  Finally, increased metabolism through the HBP in the hypothalamus 
decreased food intake and body weight and increased central and peripheral insulin 
sensitivity.  These findings have important implications to individuals living with 
diabetes.  Neuronal GLUT4 and the hypothalamic HBP both modulated whole body 
insulin sensitivity, and hence, both may be potential therapeutic targets to enhance insulin 
sensitivity, which would reduce the risk and improve management of diabetes.  Further, 
patients on insulin therapy are at risk of experiencing hypoglycemia.  Neuronal GLUT4 
may be a therapeutic target for reducing the risk of hypoglycemia as the current findings 
identified its importance in the counterregulatory response to hypoglycemia.  Finally, the 
finding that moderate hypoglycemia preconditions the brain may explain why insulin 
treated patients have no long-term cognitive impairments despite experiencing episodes 
of severe hypoglycemia.  By investigating how the brain responses to both high and low 
blood sugar, this thesis identified critical aspects of brain glucose sensing/metabolism 
that modulate whole body energy and glucose homeostasis.  
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THESIS INTRODUCTION 
Diabetes 
Diabetes is a disease characterized by chronic elevated blood sugars.  The elevated blood 
sugar is a consequence of either absolute or relative deficiency in insulin.  Insulin, a 
major regulator of systemic glucose levels, is secreted from the pancreatic β-cell in 
response to a glucose load (e.g. ingestion of food).  Insulin lowers blood glucose levels 
by stimulating glucose uptake into skeletal muscle and adipose tissue, inhibiting glucose 
release from the liver, and inhibiting glucagon  secretion.  In type 1 diabetes, pancreatic 
β-cells are destroyed leading to an absolute insulin deficiency.  Type 2 diabetes is 
characterized by insulin resistance and relative insulin deficiency.  In both cases, the 
abnormalities in insulin production and/or action result in elevated blood sugars.  Chronic 
hyperglycemia is toxic to cells and leads to microvascular complications such as 
retinopathy, nephropathy, and neuropathy (1;2).  Therefore, the management of both type 
1 and type 2 diabetes includes insulin therapy aimed to reduce blood sugars towards 
normal to prevent the microvascular complications associated with diabetes.  However, 
determining the precise amount of insulin needed to lower blood sugar to normal while 
avoiding hypoglycemia is difficult.  Indeed, iatrogenic hypoglycemia is a common 
complication of insulin therapy and is the major barrier to the management of diabetes 
(3).  Therefore, understanding how the body maintains glucose homeostasis may lead to 
improved therapies that reduce the risk and improve the management of diabetes. 
Glucose is the main fuel source for the brain and provides the majority of the 
nutritional needs to peripheral tissues (4).  Thus, blood glucose levels must be tightly 
controlled in order for the brain to sustain its own nutritional requirements as well as for 
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peripheral tissues to receive an appropriate amount of fuel.  If glucose homeostasis is 
disrupted, the body may become exposed to the toxic effects of chronic elevated blood 
sugars, as occurs with diabetes.  Central to maintaining glucose homeostasis is the ability 
of the brain to sense the amount of circulating glucose in the body and respond 
accordingly (5).  Impaired brain glucose sensing may impair an individual’s ability to 
sense and respond to severe hypoglycemia as occurs with tight glycemic control with 
insulin therapy, thus making them more susceptible to a loss of consciousness and 
potential neuronal injury (6).  Thus, the aim of this thesis was to investigate the 
mechanisms in which brain senses glucose as well as the adaptive responses of the brain 
to both increased glucose levels as well as decreased glucose levels.  Specifically, the 
experiments in this thesis investigated (1) the role of glucose transporter 4 (GLUT4) in 
glucosensing, (2) the effect of central hyperglycemia and the hexosamine biosynthetic 
pathway in feeding behavior, and (3) the adaptive response of the brain to recurrent, 
moderate hypoglycemia. 
 
Neuronal Glucose Sensing 
Several studies have demonstrated that the brain is exquisitely sensitive to 
changes in glucose, and brain glucose sensing is an essential component of feeding 
behavior, counterregulatory response, and peripheral glucose levels.   First, feeding 
behavior is affected by brain glucose levels (7-9).  Increasing central glucose levels by 
direct infusion of glucose into the brain reduces food intake and body weight (7;8).  
Central glucose deprivation by injection of 2-deoxy-D-glucose (a glucose analogue that is 
transported but not metabolized) into the third ventricle of the brain results in 
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hyperphagia and increased body weight (9).  In addition to modulating feeding behavior, 
brain glucose sensing also modulates the counterregulatory response to hypoglycemia 
(10;11).  In response to low blood sugar, the sympathetic nervous system is activated, 
epinephrine is released from the adrenal medulla, and glucagon is released from the α-
cells of the pancreas to increase blood glucose levels.   The brain is the critical glucose 
sensing organ that determines the counterregulatory response to hypoglycemia.  If, under 
experimental conditions, brain glucose levels are maintained at normal levels despite 
peripheral hypoglycemia, the counterregulatory response is blocked (12).  On the other 
hand, if the brain is deprived of glucose while the rest of the body is maintained at 
euglycemia, a robust counterregulatory response is produced (13).  Finally, brain glucose 
can also affect peripheral glucose levels by modulating hepatic glucose production.  
Infusion of glucose into the brain lowers blood glucose by reducing gluconeogenesis and 
glycogenolysis (14).  How the brain is able to sense these changes in ambient glucose has 
been an area of intense research. 
Identification of ―glucose responsive‖ neurons in the brain has been an important 
step forward in understanding how the brain senses changes in glucose (15;16).  These 
distinct neuronal populations are expressed in several areas of the brain including the 
hypothalamus, an area important in the regulation of whole body energy metabolism 
(15;16).   They are termed ―glucose responsive‖ neurons because their membrane 
potential and activity responds to changes in glucose.  Two types of glucose responsive 
neurons have been identified.  First, glucose excited (GE) neurons are those neurons that 
depolarize and increase activity with increases in glucose levels (15;16).  At low ambient 
glucose, GE neurons are quiescent.   The other type of glucose responsive neurons is 
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glucose inhibited (GI) neurons which reduce electrical activity at high glucose levels and 
increase their activity when ambient glucose levels are low (15;16).  The mechanism by 
which these glucosensing neurons respond to changes in glucose are only beginning to be 
understood.  Glucokinase (GK) and KATP channels have been shown to be important in 
the glucosensing ability of these cells (15;17-19).  Disruption of glucose sensing in 
hypothalamic neurons by deletion of KATP channels results in impaired whole body 
glucose tolerance (19).  Several other proteins may also be important in glucose sensing, 
and several hormones can modulate neuronal glucose sensing.  
Hormonal signals such as insulin can influence the glucose sensing properties of 
glucose responsive neurons.  The presence of insulin modulates the electrical activity of 
glucose excited neurons in response to changing glucose levels (20).  Further, the absence 
of insulin receptors in glucose excited neurons reduces the excitability of these neurons to 
increases in glucose (V. Routh, unpublished data).  However, how insulin modulates 
glucose responsive neurons are unknown.  Insulin has a plethora of potential targets from 
regulation of glucokinase, KATP activity, as well as glucose transporter 4.  The work in 
this thesis investigated the potential role of GLUT4 in modulating neuronal glucose 
sensing.   
 
Glucose Transporter 4 (GLUT4) 
Glucose transporter 4 (GLUT4) is a key protein involved in the regulation of 
glucose homeostasis.  GLUT4, one of an expanding family of sugar transporter proteins 
(21), allows facilitative diffusion of hexoses, in particular glucose, across cell 
membranes.  GLUT4 is unique in that it is mostly expressed in intracellular vesicles in an 
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unstimulated state.  Then, in response to insulin and other stimuli, GLUT4 translocates to 
the plasma membrane, and subsequently, allows the transport of glucose into the cell 
(22).  This phenomenon has been widely studied and described in peripheral tissues and 
cells such as skeletal muscle and adipocytes.  Disruption of GLUT4, whether whole body 
deletion (23) or even disruption of one GLUT4 allele (24;25) results in impaired glucose 
tolerance, impaired insulin resistance, and an increased risk of diabetes.  Tissue specific 
ablation of GLUT4 identified key roles of skeletal muscle GLUT4 (26;27) and adipocyte 
GLUT4 (28) in modulating glucose homeostasis.  Interestingly, GLUT4 is also expressed 
in the central nervous system (29-32); however, whether brain GLUT4 also plays a role 
in regulating glucose homeostasis is unknown. 
GLUT4 has been identified in specific areas of the brain, including the cortex, 
hippocampus, cerebellum, and importantly, the hypothalamus (29-32).  It is primarily 
expressed in neuronal bodies and dendrites with little or no staining in non-neuronal cells 
such as glia (29;30).  Interestingly, GLUT4 was demonstrated to be expressed not only in 
the plasma membrane but also in intracellular vesicles, similar to peripheral tissues 
(29;30).  Further, up to 75% of glucose responsive neurons in the hypothalamus co-
express GLUT4 and insulin receptor (15;16).  These histological data suggest an 
interaction between insulin signaling and GLUT4 translocation in the brain, as occurs in 
peripheral tissues.  Indeed, several studies found a correlation between the level of 
circulating insulin and GLUT4 translocation to the plasma membrane in the central 
nervous system (33).  Specifically, in conditions of hyperinsulinemia, GLUT4 protein 
expression in the plasma membrane is significantly increased (33).  In insulin-deficient 
states, GLUT4 expression in the plasma membrane is significantly reduced (34).  Cell 
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culture studies have also demonstrated GLUT4 translocation to the plasma membrane in 
response to insulin stimulation (35).  Thus, studies suggest insulin can increase GLUT4 
translocation to the plasma membrane in neurons.  However, the functional significance 
of brain GLUT4 has yet to be delineated. 
Insulin action in the brain plays an important role in energy homeostasis and is 
critical for neuronal glucose sensing.  Deletion of insulin receptor centrally results in 
peripheral insulin resistance, glucose intolerance, and increased susceptibility to diet 
induced obesity (36;37).  Further, mice that lack the insulin receptor in the brain have 
impaired counterregulatory response to hypoglycemia (38), and recent data demonstrated 
that this impaired counterregulation is associated with a reduced ability of glucose-
responsive neurons to respond to changes in glucose (39).  If GLUT4 is also important in 
exerting insulin effects centrally, then neuronal GLUT4 would be critical in modulating 
energy homeostasis and neuronal glucose sensing as well.  Thus, the experiments in this 
thesis investigated the role of GLUT4 in neuronal glucose sensing, energy homeostasis, 
and counterregulatory response to hypoglycemia.  
 
Hyperglycemia and the hexosamine biosynthetic pathway 
Dysregulated glucose homeostasis as occurs with diabetes lead to chronic 
elevated blood sugars.  In addition to the toxicity of hyperglycemia to tissues, elevated 
blood sugar can further impair normal glucose homeostasis as part of a vicious cycle 
(40;41).  Hyperglycemia results in peripheral insulin resistance, and as insulin is the 
major hormone in the regulation of glucose homeostasis, further disrupts the ability to 
maintain normal blood glucose levels.  Hyperglycemia results in insulin resistance via 
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increased metabolism through the hexosamine biosynthetic pathway (HBP) (40;41).  Of 
the glucose that is transported into the cell, 2-5% is metabolized through the HBP.  The 
rate limiting enzyme in the HBP is glutamine:fructose-6-phosphate amidotransferase 
(GFAT), and the end product of this pathway is uridine diphosphate-N-
acetylglucosamine (UDP-GlcNAc) (40;41) (Figure 18).  UDP-GlcNAc can be attached to 
threonine and serine residues of proteins by O-linked β-N-acetylglucosamine transferase 
(OGT), termed O-linked glycosylation (40;41).  Glucosamine, a molecule that directly 
enters the HBP, has also been shown to mimic hyperglycemia by increasing UDP-
GlcNAc and O-linked glycosylation (40;41). 
Several studies have linked increased UDP-GlcNAc and O-linked glycosylation 
to insulin resistance.  Adipocytes and skeletal muscle cells exposed to either high 
concentrations of glucose or glucosamine results in impaired insulin-stimulated GLUT4 
translocation and, consequently, reduced insulin stimulated glucose uptake (42-44).  
Interestingly, inhibition of the HBP and reduction of O-linked glycosylation by inhibiting 
GFAT prevented the insulin resistance caused by exposure to high concentrations of 
glucose (45).  Further, increasing O-linked glycosylation by overexpression of OGT in 
adipocytes and skeletal muscle cells results in insulin resistance characterized by reduced 
insulin stimulated glucose uptake (46).  Taken together, these studies indicate a major 
role of the HBP and protein glycosylation in the development of insulin resistance due to 
hyperglycemia. 
Protein glycosylation is thought to disrupt insulin signaling by altering an array of 
signaling molecules as well as modulate transcription and translation (40).  For example, 
protein glycosylation is thought to compete with insulin signaling enzymes for 
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phosphorylation sites on target proteins.  Indeed, increased protein glycosylation reduces 
insulin-induced phosphorylation of protein kinase B (Akt) (47;48).  These effects are well 
characterized in peripheral tissues (47;48).  However, the effect of chronic hyperglycemia 
and metabolic flux through the HBP in the CNS has not been investigated.  Indeed, 
excess nutrients by high fat feeding have been shown to disrupt neuronal glucose sensing  
(19).   
The experiments in this thesis investigate whether excess glucose specifically in 
the CNS can affect neuronal glucose sensing and alter glucose homeostasis.  Further, this 
thesis investigated whether the HBP in the hypothalamus is important in mediating the 
effects of central hyperglycemia on whole body energy homeostasis.   If a similar 
phenomenon occurs in the CNS as it does in peripheral tissues, central glucosamine 
infusion into the hypothalamus and subsequent increases in protein glycosylation is 
hypothesized to induce neuronal insulin resistance.  Central insulin resistance would be 
predicted to lead to hyperphagia, increased body weight, glucose intolerance, and reduced 
peripheral insulin sensitivity (36;37).   
 
Severe Hypoglycemia 
Intact neuronal glucose sensing is imperative for preventing large fluctuations in 
glucose, including severely low blood sugar levels.  The ability to sense and respond to 
hypoglycemia is especially important for individuals who are on insulin therapy to 
control their diabetes.  The Diabetes Control and Complications Trial (DCCT) 
demonstrated that intensive insulin therapy reduces the microvascular complications 
associated with diabetes, including retinopathy, neuropathy, and nephropathy (49).  
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However, intensive insulin therapy that aims to lower blood glucose levels towards 
normal also significantly increases the risk of hypoglycemia (50).  Hypoglycemia is 
defined as a plasma glucose level less than 70 mg/dl, but varying degrees of severity of 
hypoglycemia exist (51).  Mild hypoglycemia may be asymptomatic.    Moderate 
hypoglycemia may cause hypoglycemic symptoms such as sweating, palpitations, and 
hunger and may acutely affect cognitive ability, leading to temporary stupor and 
confusion.  Further declines in blood sugar may lead to severe hypoglycemia which is 
defined as an hypoglycemic event that requires assistance from another individual to 
administer carbohydrates or glucagon to increase blood sugar (51).  Severe hypoglycemia 
can lead to seizures, coma, and death (4;52).  Thus, discovering potential mechanisms to 
protect the brain from severe hypoglycemic injury is of great importance to individuals 
on insulin therapy who are at great risk of developing severe hypoglycemia. 
 Animal studies have unequivocally shown that severe hypoglycemia leads to 
neuronal injury and long-term impairments in memory.  Severe hypoglycemia leads to 
significant neuronal damage in many areas in the brain including the cortex and 
hippocampus, areas particularly important in learning and memory (52).  This brain 
injury leads to impaired spatial learning and memory even several weeks after the 
episode of severe hypoglycemia (53;54).  Case studies in humans have shown severe 
hypoglycemia can lead to brain injury and encephalopathy (55).  While many clinical 
studies also demonstrate a correlation between severe hypoglycemia and long term 
cognitive impairments (56-66) some studies do not (67-72).  The discrepancy between 
studies could be attributed to many factors, but one variable in particular may be prior 
glycemic control (including hypoglycemia).  The strongest risk factor for experiencing 
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severe hypoglycemia is the number of prior hypoglycemic events; that is, individuals 
who have experienced antecedent hypoglycemia are at greater risk for future 
hypoglycemia (49). The reason for this, as several studies have demonstrated, is that 
antecedent hypoglycemia impairs the body’s counterregulatory response to subsequent 
hypoglycemia.  This phenomenon is termed hypoglycemia-associated autonomic failure 
(HAAF).  HAAF results from reduced sympathoadrenal responses leading to, first, 
defective glucose counterregulation (e.g. attenuated epinephrine response) and, second, 
hypoglycemic unawareness (HU), the reduction of neurogenic symptoms (sweating, 
palpitations, etc.) at a given level of hypoglycemia (3;73).  Attenuated epinephrine 
responses increase the risk for severe hypoglycemia by 25-fold (74), and patients with 
HU have a six-fold increased risk for developing severe hypoglycemia (75).   
This situation seems paradoxical in that the body seemingly maladapts to 
hypoglycemia by limiting its ability to defend against subsequent hypoglycemia. Several 
studies have indicated that a central nervous system (CNS) adaptation occurs after an 
episode of hypoglycemia.  The brain adapts to episodic periods of lower levels of blood 
sugar and thus the glycemic threshold for initiating glucose counterregulation and 
neurogenic symptoms is shifted to lower glucose levels.  
In other areas of brain research, the term preconditioning refers to the exposure to 
a sublethal stressful stimuli (e.g. ischemia) that will result in protection against larger 
doses of that same stressful stimuli (76).  One of the first studies of preconditioning in 
animals found that rats exposed to brief anoxia had significantly increased survival 
following a subsequent exposure to prolonged anoxia (77).  Further, hippocampal cell 
death after global ischemia is completely prevented when carotid blood flow is briefly 
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interrupted (resulting in mild ischemia) a few days before exposure to global ischemia 
(78).  Clinical studies also support this phenomenon.  Several studies have suggested that 
prior transient ischemic attacks precondition the brain and improve outcomes in people 
who experience stroke (79-81).  The phenomena of preconditioning has also been 
described in other paradigms, including systemic hyperthermia, responses to 
lipopolysaccharide injections, and in response to various anesthetics (76).  However, no 
study has investigated the possibility of recurrent hypoglycemia as a preconditioning 
stimulus.  As stated earlier, antecedent hypoglycemia leads to adaptations within the 
brain that cause HAAF, presumably by allowing the brain to better tolerate and be less 
response to hypoglycemia (6;82).  Intensively insulin treated people that experience 
severe hypoglycemia also have recurrent episodes of moderate hypoglycemia.  Further, 
some studies suggest no long term cognitive impairments due to severe hypoglycemia in 
humans (67-72).  Taken together, this thesis hypothesizes that recurrent moderate 
hypoglycemia can act to precondition the brain and protect it against neuronal injury and 
cognitive decline induced by severe hypoglycemia.  Hypoglycemic preconditioning thus 
may explain why several clinical studies found no association between severe 
hypoglycemia and long-term cognitive dysfunction. 
 
The ability of the brain to sense and respond to changes in blood glucose is critical to 
maintain glucose homeostasis.  Disruption of the ability of the brain to sense and respond 
to changes in glucose occurs in pathological conditions of chronic hyperglycemia 
(diabetes) as well as hypoglycemia.  Thus, the work of this thesis investigated the 
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mechanisms of brain glucose sensing and metabolism that are essential to glucose 
homeostasis and preserving neuronal viability.   
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CHAPTER 1.  GLUCOSE INTOLERANCE, REDUCED INSULIN SENSITIVITY, 
AND IMPAIRED COUNTERREGULATORY RESPONSE TO HYPOGLYCEMIA 
IN NEURONAL SPECIFIC GLUT4 KNOCK-OUT MICE 
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ABSTRACT 
The specific role of the insulin-responsive glucose transporter 4 (GLUT4) in the brain has 
not been well characterized in spite of its unique distribution in key glucose sensing areas 
of the brain. GLUT4 was therefore selectively knocked-out in neurons using a Cre-Lox 
approach.  Brain GLUT4 protein expression was reduced by 99% in NG4KO mice 
(p<0.01) compared to littermate controls.  GLUT4 protein levels in the skeletal muscle, 
adipose tissue, and heart were unaffected by neuron-specific GLUT4 deletion (p=NS, 
ANOVA).  Despite normal fed and fasting glycemia, NG4KO mice had significantly 
higher glucose levels during a glucose tolerance test (2g/kg) compared to littermates 
(p<0.01). NG4KO mice also had impaired insulin sensitivity as assessed by 
hyperinsulinemic (4 mU/kg/min) euglycemic (~110 mg/dl) clamps.  NG4KO mice 
required a significantly lower glucose infusion rate to maintain euglycemia compared to 
littermate controls (p<0.05), and insulin-induced suppression of hepatic glucose 
production was impaired in NG4KO (p<0.02 vs controls).  To assess the role of brain 
GLUT4 in glucose sensing, hyperinsulinemic (30 mU/kg
/
min) hypoglycemic (~33 mg/dl) 
clamps were performed in awake, cannulated, unrestrained mice. Epinephrine and 
glucagon responses to hypoglycemia in NG4KO mice were significantly reduced by 48% 
and 54%, respectively, while norepinephrine and corticosterone responses were normal.  
Additionally, c-fos activation in the hypothalamic paraventricular nucleus in response to 
hypoglycemia was significantly reduced in NG4KO compared to littermate controls 
(p<0.01).  Thus, the impaired counterregulatory response to hypoglycemia, reduced 
insulin sensitivity, and impaired glucose tolerance in NG4KO mice indicate a critical role 
for brain GLUT4 in sensing and responding to changes in blood sugar.    
3 
 
INTRODUCTION 
The facilitative glucose transporter 4 (GLUT4) is the major glucose transporter in 
skeletal muscle and adipose tissue.  In response to insulin stimulation, GLUT4 is 
translocated to the plasma membrane and facilitates glucose entry into the cell (83-85).  
Disruption of GLUT4 in either skeletal muscle or adipose tissue leads to impaired 
glucose tolerance and insulin resistance, two key features in the pathogenesis of diabetes 
(26;28).  Recently, GLUT4 has been found to be expressed in the brain (30;31;86-88).  
However, the physiological role of GLUT4 in the brain has yet to be elucidated.  GLUT4 
is expressed predominantly in neuronal cells in discrete regions of the brain, including the 
hippocampus, cortex, and cerebellum.  Of particular interest is that GLUT4 is also 
expressed in the hypothalamus, an area important in the regulation of whole body glucose 
and energy homeostasis (30;31;86-88).  Further, GLUT4 is co-expressed with the insulin 
receptor in important glucose sensing areas of the brain including in glucose excited (GE) 
neurons in the mediobasal hypothalamus (15).  Thus, central GLUT4 may play an 
important role in the neuronal glucose sensing and modulating whole body glucose 
homeostasis.   
To determine the physiological roles of GLUT4 in the brain, GLUT4 was 
selectively knocked-out in neuronal tissue using a Cre-Lox approach and the effects on 
whole body glucose homeostasis were examined.  Mice with the neuronal specific 
GLUT4 knock-out (NG4KO) were found to be glucose intolerant, have reduced insulin 
sensitivity, and impaired counterregulatory responses to hypoglycemia.  Thus, these 
studies found a novel role for GLUT4 in regulating whole body energy homeostasis.   
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MATERIAL AND METHODS 
Animals.  Mice that have the GLUT4 gene floxed (Lox) (26;28) were crossed with 
transgenic mice that expressed Cre recombinase under the neuron specific promoter 
nestin (36;38;89).  The resultant heterozygotes were crossed with each other to produce 4 
experimental groups:  wild-type (WT); mice that have both GLUT4 alleles floxed (Lox);  
nestin-Cre expressing mice (Cre); and knockout mice that express both nestin-Cre and 
have both GLUT4 alleles floxed (NG4KO).  Mice were genotyped by PCR analysis of 
DNA extracted from tail tissue and using previously established primers and PCR 
conditions (26;28;36;38). 
Mice were housed in a temperature and light controlled environment maintaining 
the animal’s diurnal cycle (12hrs light, 12hrs dark) and fed a standard rodent chow or a 
high fat diet (60% calories from fat, Research Diets 12492; New Brunswick, NJ) ad 
libitum.  Male Sprague-Dawley rats were individually housed, maintain on a 12 hour 
light/12 hour dark cycle, and fed standard rodent chow diet.  All procedures were in 
accordance with the Guide for the Care and Use of Laboratory Animals of the National 
Institutes of Health and were approved by the Animal Studies Committee of Washington 
University. 
Western blot analysis.  Brain, skeletal muscle, heart, and white adipose tissue 
were homogenized in buffer containing 1% Igepal (Sigma, Saint Louis, MO), 0.5%  
sodium dodecyl sulfate (Sigma, Saint Louis, MO), 0.1 mM Phenylmethylsulfonyl 
fluoride (Sigma, Saint Louis, MO), 1X complete protease inhibitor (Sigma, Saint Louis, 
MO), 1 mM NaF (Sigma, Saint Louis, MO), and 1 mM Na3VO4 (Sigma, Saint Louis, 
MO) in phosphate buffered saline (pH=7.4), centrifuged at 14,000 rpm for 30 min, and 
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supernatant was collected.  Protein samples  were then separated on 4-12% Bis-Tris Gel 
(Invitrogen, Carlsbad, CA), transferred to nitrocellulose membrane (Bio-Rad, Hercules, 
CA), and were immunoblotted with antibodies against GLUT1 (1:1000, Chemicon, 
Temecula, CA), GLUT3 (1:2000, Chemicon, Temecula, CA), GLUT4 (1:1000, 
Chemicon, Temecula, CA), or against the loading control β-actin (1:6000; Sigma, St. 
Louis, MO).  Horseradish peroxidase-conjugated secondary antibody (1:8000, Cell 
Signaling, Boston, MA) was used and antibody binding was detected by enhanced 
chemiluminescence ECL reagents (Perkin Elmer, Waltham, MA) on ISO-MAX films and 
quantified by ImageJ software analysis. 
Glucose and insulin tolerance tests.  Glucose tolerance tests (GTT) were 
accomplished by intraperitoneal injection of glucose (2 g glucose/kg body weight) after 
an overnight fast (15-17 hr).  In addition to glucose sampling, tail vein blood samples (20 
μl) were taken before glucose injection and at 15 minute intervals during the GTT to 
measure plasma insulin levels.  Insulin tolerance tests (ITT) were performed in 5 hour 
fasted mice by intraperitoneal injection of human regular insulin (1 U insulin/kg body 
weight; Lilly, Indianapolis, Indiana).  Tail vein blood glucose was measured using 
Ascensia Contour blood glucose monitors (Bayer, Tarrytown, NY). 
Glucose stimulated insulin secretion.  First phase glucose stimulated insulin 
secretion was assessed by an intraperitoneal injection of glucose (3 g glucose/kg body 
weight) in fasted (15-17 hr) mice.  Tail vein blood glucose was measured and blood 
samples (20 μl) were collected for plasma insulin determinations immediately before 
injection and at 2, 5, 15, and 30 minutes after injection.   
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High-Fat Feeding.  At 5-6 weeks of age, male NG4KO mice and their littermate 
controls were fed a high fat diet (60% calories from fat, Research Diets 12492; New 
Brunswick, NJ) for 11 weeks.  Body weight was measured before the start of the high fat 
diet and weekly during the high fat feeding.  Tail vein blood glucose was measured 
before the start of the high fat diet and at the end of the 11 week high fat feeding.  
Glucose tolerance and insulin tolerance tests were performed after 11 weeks of high fat 
feeding. 
Hyperinsulinemic-euglycemic clamp, glucose kinetics analysis, and brain 
glucose uptake. Micro-renathane catheters (Braintree Scientific Inc., Braintree, 
Massachusetts, USA) were implanted in the jugular vein and femoral artery of 
anesthetized mice (Ketamine 87 mg/kg and Xylazine 2.6 mg/kg). Hyperinsulinemic-
euglycemic clamp studies were conducted 5–8 days after surgery in awake, freely mobile 
mice after a 5-hour fast.  Whole-body glucose flux was determined using a continuous 
infusion of [3-3H] glucose (PerkinElmer, Boston, Massachusetts, USA) at 0.05 μCi/min 
after an initial 5-μCi bolus.  After a 90 minute basal period, one basal blood sample (25 
µl) was taken for measurement of basal plasma insulin levels and three basal blood 
samples (15 μl) at 10 min intervals were taken for plasma [3H]glucose measurements.  
After basal sampling, a primed (40 mU/kg) continuous infusion (4 mU/kg/min) of human 
regular insulin (Humulin; Eli Lilly and Co.) in 0.1% BSA was co-administered with 50% 
glucose at variable rates to maintain blood glucose at approximately 110 mg/dl.  Arterial 
blood glucose (~2 ul) was measured every 10 min.   
Tissue-specific insulin-stimulated glucose transport was measured from a bolus (5 
μCi) of 2-deoxy-D-[1-14C] glucose (2-[14C]DG; Amersham)  administered 45 minutes 
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before the end of the clamp. For plasma 2-[14C]DG measurements, blood samples (10 μl) 
were taken immediately before 2-[14C]DG administration and at 0.5, 2, 3, 5, 10, 15, 20, 
30, and 45 min following administration.   For plasma [3H]glucose measurements, 20 
min before the end of the clamp, blood samples (15 μl) were taken at 10 min intervals till 
the end of the clamp, and a 25 µl blood sample was taken at the end of the clamp to 
measure plasma  insulin levels.  Immediately after the conclusion of the clamp, animals 
were euthanized and skeletal muscle and adipose tissue rapidly were dissected and frozen 
in liquid nitrogen.  Brains were rapidly harvested and quickly frozen in a dry ice and 2-
methylbutane (Fisher, Saint Louis, MO)  bath (-20
o
 C).  Plasma [3-3H] glucose and 2-
[14C]DG concentrations were determined by a dual-channel scintillation counter (Tri-
Carb 2800TR, PerkinElmer, Waltham, MA) after deproteinization and drying. Tissue 2-
[14C]DG and 2-[14C]DG-6-phosphate (2-[14C]DG-6P) were separated by ion-exchange 
chromatography. 
Whole-body glucose turnover was determined during the steady state from the 
ratio of the [3H] glucose infusion rate to the measured specific activity of plasma glucose 
(90). Hepatic glucose production (HGP) was determined by subtraction of the glucose 
infusion rate from the whole-body glucose turnover (90).  Skeletal muscle and adipose 
tissue glucose uptake was calculated from tissue 2-[14C]DG-6P content normalized 
against the area under the plasma 2-[14C]DG decay curve (91).   
For brain glucose uptake calculations, isotope concentrations in regions of interest 
were measured from 20μm thick coronal brain sections after exposure to autoradiograph 
film via optical densitometry. Precise identification of the areas of interest 
(paraventricular nucleus of the hypothalamus (PVN), arcuate nucleus (ARC), 
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ventromedial hypothalamus (VMH), hippocampus, cerebellum, and cortex) were 
accomplished by Nissl staining the radiolabeled sections and visualizing the desired areas 
(Figure 8).   Mean local rates of glucose utilization were averaged from four matched 
sections from each region of interest then calculated according to Sokoloff’s equation 
with rat rate constants, as mice rate constants have not been determined (92;93). 
 Pharmacological inhibition of brain GLUT4 by indinavir (IDV).  Cannulas 
(Plastics One Inc, Roanoke, VA) were inserted in the third ventricle, and micro-
renathane® (Braintree Scientific, Boston, MA) catheters was inserted into the left carotid 
artery and right jugular vein in anesthetized (Ketamine 87 mg/kg and Xylazine 2.6 
mg/kg) nine week-old male Sprague Dawley rats. After one week of recovery, the 
animals were subjected to an hyperinsulinemic (20 mU/kg/min) hypoglycemic clamp 
(~45 mg/dl).  Three hours prior to the start of and for the duration of the clamp, indinavir 
(10μg/min; Merck, White-house City, NJ) or vehicle (artificial cerebrospinal fluid, aCSF) 
was infused into the third ventricle.  Indinavir is a pharmacologic agent that has been 
shown to inhibit GLUT4 activity and transport in cell culture and hippocampal brain 
slices (94-96).  Blood samples were taken in the basal period and at 45, 60, and 90 min 
into the hyperinsulinemic hypoglycemic clamp. 
  Hyperinsulinemic-hypoglycemic mice clamps and c-fos immunostaining. Four 
month old mice anesthetized with ketamine/xylazine (87 and 13.4 mg/kg IP) were 
implanted with micro-renathane catheters (Braintree Scientific Inc., Braintree, MA) into 
both the right internal jugular vein and  femoral artery. After a 5-7 day recovery period, 2 
hour hyperinsulinemic (20mU/kg/min) hypoglycemic (30 mg/dl) clamps were performed 
in 5-hour fasted, freely mobile mice.  A variable 12.5% glucose infusion was used to 
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carefully match blood glucose levels to 30 mg/dl.  Arterial blood samples (~2 μl) were 
drawn at 10-min intervals to measure blood glucose (Ascenia Contour blood glucose 
monitor).  Blood samples (110 μl) were taken in the basal period and at 50 and 90 min 
into the hyperinsulinemic hypoglycemic clamp to assess the counterregulatory response.   
At the end of the 2 hr hypoglycemic clamp, mice anesthetized with isofluorane 
and intracardially perfused with 0.01 M PBS (Sigma, Saint Louis, MO) followed by 4% 
paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA).  The brains were 
immersed in 4% paraformaldehyde overnight and then cryoprotected in 30% sucrose.   
Brain sections were then processed for c-fos immunostaining.  Free-floating brain 
sections (20µm) were blocked with 30% normal goat serum diluted in 0.1% Triton-
100/PBS and then incubated overnight at 4°C with c-fos antibody (1:2000, Ab-5, 
Calbiochem). Subsequently, the sections were mounted on slides and processed with 
biotinylated goat anti-rabbit immunoglobulin G (1:200) using the Elite ABC kit (Vector 
Laboratories).  Four anatomically matched sections per animal were used to quantify c-
fos immunostaining in the paraventricular nucleus of the hypothalamus (PVN).  c-fos 
data was expressed as the average number of c-fos positive cells per section.  An observer 
blinded to the mice genotype counted the number of c-fos positive cells in the PVN. 
Brain Glucose Uptake during a hyperinsulinemic-hypoglycemic clamp. 
Awake, unrestrained, cannulated NG4KO and littermate Lox mice underwent a 2-hour 
hyperinsulinemic (80mU/kg/min) hypoglycemic (30mg/dL) clamp protocol. The 
experiments were similar in design to the euglycemic clamps noted above, except that the 
clamps were performed during hypoglycemia when glucose uptake into the brain may be 
rate limiting.  At 45 minutes prior to the end of the clamp, a 5μCi bolus of 
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2[14C]deoxyglucose was administered intravenously and arterial blood samples (10 μl) 
were collected immediately before 2[14C] deoxyglucose injections and 0.5, 2, 3, 5, 10, 
15, 20, 30, and 45 min following administration for analysis of arterial plasma glucose 
and plasma 2-[14C]DG levels. Isotope concentrations and brain glucose utilization in 
PVN, ARC, VMH, hippocampus, cerebellum, and cortex were measured as described 
above.   
Heat Stress.  Awake NG4KO and littermate control mice were exposed to an 
ambient temperature of 42°C for 60 minutes to induce heat stress. Blood samples were 
taken before and at the end of the heat stress period to measure epinephrine levels.  
Analytical measurements.  Blood glucose was measured by Ascensia Contour 
blood glucose monitors (Bayer HealthCare, LLC, Mishawaka, IN).  Insulin levels were 
measured by enzyme-linked immunosorbent assay (ELISA) (Crystal Chem, Chicago, 
Illinois).  Catecholamine analysis was performed by a single isotope-derived 
(radioenzymatic) method (97). Radioimmunoassays were performed for glucagon (Linco 
Research, St. Charles, MO) and corticosterone (MP Biomedicals, Orangeburg, NY) 
measurements. 
Statistical analyses.  All data are presented as the mean  standard error of the 
mean (SEM).  Statistical significance was set at p<0.05 and was determined by either 
Student’s t test or analysis of variance (ANOVA), as indicated. 
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RESULTS 
Verification of neuronal-specific GLUT4 deletion 
Using the Cre-Lox system, neuronal specific GLUT4KO mice were created by 
crossing mice that express Cre under the nestin promoter with mice that have exon 10 of 
GLUT4 flanked by loxP sites.  Four experimental groups were generated:  wild-type mice 
(WT); mice with both GLUT4 genes floxed (Lox); mice that express Cre under the nestin 
promoter (Cre); and neuronal specific GLUT4 knockout mice (NG4KO) mice.  To verify 
tissue specific deletion of GLUT4, GLUT4 protein concentration was measured by 
Western Blot analysis in the brain as well as the muscle, heart, and white adipose tissue.  
NG4KO mice had a greater than 99% reduction in brain GLUT4 protein levels relative to 
WT, Lox, and Cre mice (Figure 1).  Importantly, GLUT4 content in the heart, muscle, 
and adipose tissue was present in NG4KO mice and expressed at similar levels to the 
littermate controls (Figure 1), verifying the specificity of the brain GLUT4 knock-out. 
To determine if deletion of GLUT4 in the brain altered expression of other brain 
glucose transporters, GLUT1 and GLUT3 protein expression were measured by Western 
blot.  No significant difference in whole brain GLUT1 and GLUT3 protein levels were 
observed between NG4KO and littermate controls (Figure 2).   
 
Effect of Brain GLUT4KO on energy and glucose homeostasis. 
Body weight was measured weekly from 5 weeks to 12 weeks of age.  No 
significant difference in body weight was observed between Cre mice and NG4KO mice 
in both males and females (Figure 3).  Intriguingly, both Cre and NG4KO mice had 
significantly reduced body weights compared to WT and Lox mice (Figure 3).  No 
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significant difference in body weight was observed between WT and Lox mice (Figure 
3).  Thus, the expression of Cre itself reduced body weight.   
The reduction in body weight was partly attributable to the reduction in body 
length.  Crown-rump body length was measured at 12 weeks of age and, consistent with 
the body weight, Cre and NG4KO were significantly shorter than WT and Lox mice 
(Figure 3).  Brain mass was not significantly different between groups nor were fat pad 
mass (Figure 3). 
 
Neuronal GLUT4KO does not affect fasting or fed blood glucose levels, but results in fed 
hyperinsulinemia and glucose intolerance. 
To assess the effect of the brain GLUT4 KO on whole-body glucose homeostasis, 
fed and fasting glucose and insulin levels were measured and intraperitoneal glucose 
tolerance tests (IPGTT) and insulin tolerance tests (ITT) were performed in 12 week old 
mice on a normal chow diet.  Fasting and random fed glucose levels were similar in all 
groups in both male and female mice.  Further, in male mice, no difference in fasting or 
fed insulin levels were observed between groups (Figure 4A).  Interestingly, female 
NG4KO mice had significantly higher fed plasma insulin levels compared to WT, Lox, 
and Cre littermates, though no difference was observed with fasted plasma insulin levels 
(Figure 4D). 
The role of neuronal GLUT4 in handling and responding to changes in glucose 
was assessed by the administration of intraperitoneal glucose tolerance tests (IPGTT; 2 
mg/kg) in overnight fasted mice.  Interestingly, male NG4KO mice had significantly 
higher glucose excursions during the GTT than WT, Lox, and Cre littermates (Figure 
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5A).  In female mice, glucose increased similarly in NG4KO and littermate controls 
(Figure 5B).    To determine whether neuronal GLUT4 deletion also affected whole body 
insulin sensitivity, an insulin tolerance test (ITT, 1 U/kg) was performed in NG4KO and 
control mice.  Despite the impaired glucose tolerance, male NG4KO mice had similar 
reduction in blood glucose in response to insulin compared to littermate controls (Figure 
5).  Further, no difference in insulin sensitivity as measured by the insulin tolerance test 
was observed between the groups in female mice (Figure 5).   
The impaired glucose tolerance in male NG4KO was not attributed to altered 
glucose stimulated insulin secretion (GSIS).  Plasma insulin levels were measured during 
the IPGTT, and no difference in first phase insulin secretion and no difference in plasma 
insulin release during the glucose tolerance test were observed between NG4KO and their 
littermate controls (Figure 6). 
 
NG4KO had reduced insulin sensitivity and hepatic insulin resistance 
Although blood glucose dropped similarly in all groups in response to insulin 
during the ITT, suggesting no difference in insulin sensitivity between NG4KO and their 
littermate controls, several variables can compound these results, such as differences in 
the counterregulatory response to hypoglycemia (discussed below).  The gold standard 
for measuring insulin sensitivity and glucose kinetics is the use of the hyperinsulinemic 
euglycemic clamp.  The effect of neuronal GLUT4 KO on whole body insulin sensitivity 
was directly assessed by 2-hour hyperinsulinemic-euglycemic clamp in NG4KO mice 
and their littermate controls.   For statistical purposes, the three littermate control groups 
(WT, Lox, and Cre) were combined (CON) as there was no statistical differences 
between these control groups.   Baseline blood glucose and blood glucose during the 
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clamp were not statistically different between the NG4KO and CON (Figure 7A).  
Interestingly, NG4KO mice required 22% lower glucose infusion rate (34 ± 3 versus 43 ± 
2 mg/kg/min; p < 0.02) to maintain euglycemia compared to littermate controls, 
demonstrating whole-body insulin resistance (Figure 7B).  The defect in whole-body 
insulin sensitivity in NG4KO mice was not due to changes in glucose disposal (Rd), 
because NG4KO mice had similar basal Rd and similar insulin-stimulated increase in Rd 
compared with controls (Figure 7C).  Consistent with the similar Rd values between 
groups, no difference in 
14
C-2-deoxyglucose determined muscle and fat-specific glucose 
uptake was observed between NG4KO and CON mice (Figure 7D and Figure 7E).  
However, the ability of insulin to suppress hepatic glucose production (HGP) was 
impaired by 44% in NG4KO compared to littermate controls (Figure 7F, p < 0.02).  
To determine whether deletion of GLUT4 in the brain results in altered glucose 
uptake, brain glucose uptake was measured using 
14
C-2-deoxyglucose isotope 
determinations during the 2-hour hyperinsulinemic  (4mU/kg/min) euglycemic clamp. 
Mean local rates of glucose uptake were calculated according to Sokoloff’s equation (92).  
Deletion of neuronal GLUT4 did not result in any detectable changes in brain glucose 
uptake in select regions of the hypothalamus—the paraventricular nucleus (PVN), 
ventromedial hypothalamus (VMH), and arcuate nucleus (ARC)—as well as in the 
hippocampus, cerebellum, and cortex (Figure 8).   
 
Neuronal GLUT4 deletion does not affect susceptibility to diet-induced obesity 
Because brain GLUT4 may have a role in modulating glucose sensing, the 
deletion of brain GLUT4 may result in altered ability to sense and/or respond to 
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alterations in nutrient levels within the hypothalamus.  Impaired nutrient sensing is 
hypothesized to increase susceptibility to diet-induced obesity.  To test whether NG4KO 
are at higher risk of developing diet-induced obesity, male NG4KO mice and their 
littermate controls were fed a high-fat diet (HFD, 60% kcal from fat) starting at 5 weeks 
of age.  Body weight was measured weekly and random fed blood glucose was measured 
before the start of high fat feeding and at 11 weeks after.  No difference in body weight 
change was observed between WT, Lox, Cre, and NG4KO mice on a HFD (Figure 9).  
Random fed glucose was similar between groups before and after the high fat diet (Figure 
9).  Further, blood glucose levels during a IPGTT (2 mg/kg) and ITT (1 U/kg) were not 
different between NG4KO and littermate control mice (Figure 9). 
 
Role of central GLUT4 on the counterregulatory response (CRR) to hypoglycemia 
 Pharmacological inhibition of central GLUT4 indinavir attenuates the 
counterregulatory response to hypoglycemia.   
To test whether brain GLUT4 is important in the counterregulatory response to 
hypoglycemia, indinavir, a GLUT4 inhibitor, or vehicle (artificial cerebrospinal fluid, 
aCSF) was infused into the third ventricle (10 µg/min) of chronically cannulated rats 
during a hyperinsulinemic (20 mU/kg/min) hypoglycemic clamp.  Indinavir (IDV) is a 
pharmacologic agent that has been shown to inhibit GLUT4 activity and transport (94-
96).  Blood glucose was not different in the basal period or during the hyperinsulinemic 
clamp period (Figure 10A).  Further, no difference in epinephrine, norepinephrine, 
glucagon, and corticosterone was observed in the basal period.  Interestingly, during the 
clamp, the glucose infusion rate required to maintain glucose at ~50 mg/dl was 44% 
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higher in the IDV-treated rats compared to controls (Figure 10, P<0.05).  The higher 
glucose infusion rates in IDV rats were associated with significantly attenuated 
counterregulatory response in these animals.  Specifically, third ventricle infusion of IDV 
resulted in a 24% lower epinephrine response, a 22% lower norepinephrine response, and 
a 45% reduced glucagon response to hypoglycemia compared to controls (Figure 10).   
 
Genetic deletion of neuronal GLUT4 impairs the CRR to hypoglycemia 
A genetic approached was used to further elucidate the role of neuronal GLUT4 
in the CRR to hypoglycemia.  Hyperinsulinemic (20 mU/kg/min) hypoglycemic (~30 
mg/dl) clamps were performed in chronically cannulated, freely mobile NG4KO mice 
and their littermate controls.  Glucose levels during the basal period were similar and 
glycemia was carefully matched during the clamp period (Figure 11).   
Basal epinephrine levels were similar in all groups (Figure 11B).  During 
hypoglycemia, epinephrine levels rose similarly in the WT, Lox, and Cre mice (3133 ± 
600; 2902 ± 560; 2633 ± 355 pg/ml, respectively; P=NS).  However, epinephrine 
response in NG4KO was significantly lower (1575 ± 101 pg/ml) compared to the other 
three littermate controls (P < 0.05) (Figure 11B).  Further, glucagon response to 
hypoglycemia was significantly attenuated in NG4KO mice (NG4KO:  299 ± 92 pg/ml 
and WT 650  ± 57; Lox  597 ± 74; Cre 651 ± 39 pg/ml, p < 0.001) (Figure 11C).  
Norepinephrine and corticosterone response to hypoglycemia were not significantly 
different between the 4 groups (Figure 11D and Figure 11E).    
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Neuronal GLUT4KO results in reduced neuronal activation in the paraventricular 
nucleus in response to hypoglycemia. 
To determine whether the impaired counterregulatory response in the NG4KO 
mice was mediated by an impaired neuronal activation in response to hypoglycemia, c-
fos activation in response to hypoglycemia was measured in the paraventricular nucleus 
(PVN) at the end of the 2 hour hyperinsulinemic hypoglycemic clamps.  Despite matched 
levels of hypoglycemia, NG4KO mice had  ~80% reduction in c-fos positive cells 
compared to littermate controls (KO  28 ± 17 versus WT 120 ± 20, Lox 138 ± 19, Cre 
141 ± 20 c-fos positive cells, P < 0.001) (Figure 12).   
 
Brain glucose uptake during hypoglycemia 
Whether altered brain glucose uptake during hypoglycemia was associated with the 
impaired CRR to hypoglycemia, brain glucose uptake was measured using the 
14
C-2-
deoxyglucose radioisotope determinations during hyperinsulinemic (80mU/kg/min) 
hypoglycemic (~30 mg/dl) clamps.  No significant difference in brain glucose uptake was 
observed in NG4KO mice compared to Lox littermate controls in any of the regions 
measured (Figure 13). 
 
Impaired adrenomedullary response to stress is unique to hypoglycemia 
The reduced epinephrine response to hypoglycemia in NG4KO mice may be due 
to a generalized impairment in the adrenomedullary response to stress rather than a 
specific impairment in the ability to respond to low blood sugar.  To test the 
adrenomedullary response to other types of stress, epinephrine levels were measured 
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from tail vein blood samples drawn from NG4KO mice and littermate controls that were 
subjected to 60 min of heat stress.  No significant difference in epinephrine or 
norepinephrine levels during heat stress was observed between NG4KO and littermates 
(Figure 14). 
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Figure 1.  Brain-specific deletion of GLUT4.  (A)  Whole brain, gastrocnemius muscle, 
heart, and white adipose tissue (WAT) were harvested and homogenized for western blot 
analysis of GLUT4.  GLUT4 was reduced in the brain of neuronal GLUT4KO mice (KO) 
compared to wild-type mice (WT), Lox expressing (Lox) and Cre expressing (Cre) mice.  
GLUT4 protein levels in muscle, heart, and WAT were similar between KO and 
littermate controls.  (B)  Quantification of brain GLUT4 protein content.  KO (black bar, 
n=11) had a greater than 99% reduction in brain GLUT4 levels compared to WT (white 
bar, n=6), Lox (horizontal hash, n=6), and Cre (slanted hash, n=6).  * P < 0.001 vs WT, 
Lox, and Cre mice.  Data expressed as mean ± S.E.M. 
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Figure 2.  Brain GLUT1 and GLUT3 protein expression was not altered in neuronal 
GLUT4 KO mice.  (A and B) Brain GLUT1 and (C and D) Brain GLUT3 protein 
expression as measured by Western blot analysis was not different in neuronal 
GLUT4KO mice (KO, black bar, n=5) versus wild-type (WT, white bar, n=4), Lox 
(horizontal hash, n=4), and Cre (slanted hash, n=4).  Data expressed as mean ± S.E.M.  
n=4-6 per group. 
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Figure 3.  Neuronal GLUT4 knock-out did not affect body weight.  (A and B)  Body 
weight was similar between Cre (open triangle) mice and NG4KO (closed triangle) mice 
in both males (left panels) and females (right panels).  Cre and NG4KO mice had slightly 
lower body mass compared to WT (open circle) and Lox (closed circle) mice.  No 
difference in body weight was observed between WT and Lox mice.  n=10-20 mice per 
group. (C and D) The reduction in body weight was attributable to smaller crown-rump 
length in Cre (slanted hash) and NG4KO (black bar) mice compared to wild type (open 
bar) and Lox (horizontal hash) mice. n=5-7 mice per group.   (E and F) Brain mass, fat 
pad mass, and heart weight were not significantly different between groups. n=5-7 mice 
per group.  * P < 0.05 vs. WT, Lox, and Cre.  Data expressed as mean ± S.E.M. 
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Figure 4.  Normal glucose but hyperinsulinemia in neuronal GLUT4 KO (NG4KO) 
mice.  (A and B) Male NG4KO (black bar) have similar fed and fasting blood glucose 
levels as well as similar fed and fasting plasma insulin levels compared to wild-type 
(open bar), Lox (horizontal hash), and Cre (slanted hashed).  (C)  Female NG4KO mice 
had similar fed and fasting blood glucose levels compared to littermate controls.  (D)  
Female NG4KO mice had significantly higher plasma insulin levels in the fed state 
compared to littermate controls.  No difference in fasted plasma insulin levels were 
observed.  * P < 0.05 vs. WT, Lox, Cre.  Data expressed as mean ± S.E.M.  n=6-14 mice 
per group. 
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Figure 5.  Impaired glucose tolerance in NG4KO mice.  Intraperitoneal glucose 
tolerance tests (IPGTT, 2 mg/kg) were performed in 12 week old male and female mice.  
(A) Male NG4KO mice (closed triangles) had significantly higher excursions in blood 
glucose compared to WT (open circles), Lox (closed circles), and Cre (open triangles) 
mice.  (B) No difference in blood glucose during the IPGTT was observed in female 
NG4KO mice compared to littermate controls.  No difference in the blood glucose was 
observed between NG4KO mice and to littermate controls during an insulin tolerance test 
in either males (C) and females (D).  * P < 0.05 vs. WT, Lox, Cre.  Data expressed as 
mean ± S.E.M. n=7-17 mice per group. 
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Figure 6.  Normal glucose stimulated insulin secretion in neuronal GLUT4 knock-
out mice.  (A)  Insulin secretion during a glucose tolerance test was similar between 
NG4KO (closed triangle, n=4), wild-type mice (open circle, n=9), and lox mice (closed 
circles, n=4) (p=NS).  (B)  In a separate study, first phase insulin secretion was measured 
during after an intraperitoneal injection of glucose in NG4KO (closed triangle, n=7) and 
Cre littermate controls (open triangle, n=8).  First phase insulin secretion was not 
significantly different between groups.  Data expressed as mean ± S.E.M. 
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Figure 7.  Reduced insulin sensitivity and hepatic insulin resistance in NG4KO mice.  
(A)  Blood glucose during a hyperinsulinemic (4 U/kg/min) euglycemic clamp.  No 
difference in blood glucose before or during the clamp was observed between NG4KO 
(closed triangles, n=12) and littermate controls (CON, open triangles, n=20).  (B) Despite 
matched blood glucose levels, NG4KO mice (closed triangles, n=12) required a 
significantly lower glucose infusion rate to maintain euglycemia compared to CON (open 
triangles, n=20) indicating insulin resistance (* P < 0.05, NG4KO vs. CON). (C)  Rate of 
whole body glucose disposal at baseline and during the hyperinsulinemic clamp was not 
significantly different between NG4KO (black bar, n=12) and CON (open bar, n=20).  (D 
and E)  Glucose uptake specifically in muscle (D) and adipose tissue (E) was similar 
between NG4KO (black bar, n=6) and littermate controls (white bar, n=11) during the 
hyperinsulinemic clamp. (F)  Insulin failed to suppress hepatic glucose production in 
NG4KO (black bar) mice to the same degree as control mice (white bar, n=20) (48±8 and 
79±8 % suppression, * P < 0.02)  All data expressed as mean ± S.E.M. 
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Figure 8.  Brain glucose uptake during a hyperinsulinemic hypoglycemic clamp in 
NG4KO mice.  Brain glucose uptake was measured using 
14
C-2-deoxyglucose 
autoradiography in mice that underwent a 2 hour hyperinsulinemic (4 mU/kg/min) 
euglycemic clamp.   (A) Precise identification of the areas of interest were accomplished 
by Nissl staining the radiolabeled sections (left panels), visualizing the desired areas (i.e. 
ventromedial hypothalamus (VMH, red dashed oval outline) and arcuate nucleus (red 
dashed triangular outline), and measuring the density of the outlined areas of interest on 
the respective exposed autoradiographic films (right panels).  (B)  Quantification of brain 
glucose uptake during euglycemia using the Sokoloff’s equation in NG4KO (black bar, 
n=6) and littermate control (white bar, n=11).  Brain glucose uptake during the 
hyperinsulinemic euglycemic clamp was not significantly different in NG4KO mice 
compared to littermate controls in the areas measured:  the paraventricular nucleus 
(PVN), ventromedial hypothalamus (VMH), arcuate nucleus (ARC), hippocampus, 
cerebellum, or cortex.  Data expressed mean ± S.E.M.
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Figure 9.  Neuronal GLUT4KO did not affect susceptibility to diet-induced obesity.  
Mice were fed a high fat diet (60% calories from fat, solid) at 5 weeks of age.  (A) Body 
weight gain was similar between NG4KO mice (close triangles, n=14) and their 
littermate controls (WT, open circle, n=7; Lox, closed circle, n=9; Cre, open triangle, 
n=11).  (B)  Blood glucose before and during high fat feeding.  No difference in basal 
blood sugar levels were observed between NG4KO (black bar) and  WT (white bar), Lox 
(horizontal hash), and Cre (slanted hash).  Further, blood glucose was not significantly 
different between groups after 11 weeks on a high fat diet.  Glucose tolerance and insulin 
sensitivity as measured by a glucose tolerance test (C) and insulin tolerance test (D), 
respectively, were similar between NG4KO and littermate controls after 11 weeks on a 
high fat diet.  Data expressed as mean ± S.E.M.  n=7-14 mice per group.   
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Figure 10. ICV Infusion of an inhibitor of GLUT4 transport, indinavir, reduced the 
counterregulatory response (CRR) to hypoglycemia. Indinavir (IDV, closed circle, 
n=4) or artificial cerebrospinal fluid (aCSF, open circle, n=9) was infused for 90 min 
before and for the duration of a 90 min hyperinsulinemic (20mU/kg/min) hypoglycemic 
(~50mg/dl) clamp in Sprague-Dawley rats. (A)  Blood glucose was precisely matched 
between IDV and aCSF treated rats.  (B)  Despite matched blood glucose levels, IDV 
treated rats (closed circle) required a significantly higher glucose infusion rate than 
control rats (open circle).  The higher glucose infusion rate was attributed to the 
attenuated CRR to hypoglycemia.  Epinephrine (C), norepinephrine (D), and glucagon 
(E) response to hypoglycemia was significantly reduced in IDV rats versus controls (* 
p<0.05 by ANOVA).  Data expressed mean ± S.E.M. 
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Figure 11.  Neuronal GLUT4KO mice had impaired counterregulatory response to 
hypoglycemia.  NG4KO and their littermate controls were subjected to hyperinsulinemic 
(20 mU/kg/min) hypoglycemic (~30 mg/dl) clamps. (A) Blood glucose was not different 
before or during the clamp between NG4KO (black bar, n=5), wild-type (white bar, n=5), 
Lox (horizontal hash, n=6), and Cre (diagonal hash, n=11).  Epinephrine (B) and 
glucagon (C) responses to hypoglycemia were significantly reduced in NG4KO (black 
bar) mice compared to WT (closed bar), Lox (horizontal hash), and Cre (slanted hash).  
Norepinephrine (D) and corticosterone (E) levels during the hypoglycemic clamp were 
similar  in all groups.  * P < 0.05 versus WT, Lox, and Cre.  Data expressed as mean ± 
S.E.M.
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Figure 12.  Reduced neuronal activation in response to hypoglycemia in neuronal 
GLUT4KO mice.  Hypoglycemia was induced for 2 hours using a hyperinsulinemic (20 
mU/kg/min) hypoglycemic (~30mg/dl) clamp in NG4KO mice and their littermate 
controls.  After 2 hours, brains were harvested and processed for c-fos immunostaining.  
(A) Representative c-fos immunostaining of the hypothalamic paraventricular nucleus 
(PVN) in wild-type (WT) and NG4KO (KO) mice after 2 hours of hypoglycemia.  (B)  
Quantification of c-fos immunostaining.  The number of c-fos positive cells in the PVN 
was greatly reduced in NG4KO mice (black bar) compared to wild-type (open bar), Lox 
(horizontal hash), and Cre (slanted hash).  * P < 0.01 versus WT, Lox, and Cre.  Data 
expressed as mean ± S.E.M.  n=4-8 per group. 
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Figure 13. Neuronal GLUT4 deletion does not alter brain glucose uptake during 
hypoglycemia.  Brain glucose uptake was measured using 
14
C-2-deoxyglucose 
autoradiography in mice that underwent a 2 hour hyperinsulinemic hypoglycemic clamp.  
Brain glucose uptake during hypoglycemia was quantified using the Sokoloff’s equation 
in NG4KO (black bar, n=4) and Lox (horizontal hash, n=5).  No difference in glucose 
uptake during hypoglycemia was observed between groups in either the paraventricular 
nucleus (PVN), ventromedial hypothalamus (VMH), arcuate nucleus (ARC), 
hippocampus, cerebellum, or cortex.  Data expressed mean ± S.E.M.  
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Figure 14.  Normal sympathoadrenal response to heat stress in neuronal specific 
GLUT4 knock-out mice.  To assess the whether the adrenomedullary response in 
NG4KO was also impaired to other forms of stress aside from hypoglycemia, NG4KO 
and littermate controls (CON) were subjected to 60 min of heat stress (ambient 
temperature of 42
o
 C).  In response to heat stress, NG4KO and CON mice had similar 
increases in norepinephrine (A) and epinephrine (B). 
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DISCUSSION 
 Based on immunohistochemical studies that identified GLUT4 in discrete areas of 
the central nervous system including the hypothalamus (30;31;86-88), neuronal GLUT4 
has long been speculated to play a key role in neuronal glucose sensing and in whole 
body energy homeostasis.  However, the physiological roles of GLUT4 in the central 
nervous system have remained unknown.  This current study demonstrated a novel role of 
neuronal GLUT4 in the modulation of whole body energy homeostasis as well as the 
counterregulatory response to hypoglycemia. 
 Tissue specific deletion of neuronal GLUT4 was accomplished by Cre-Lox 
technology.  As expected, brain GLUT4 was specifically knocked out while GLUT4 
protein expression was still normally expressed in peripheral tissues including the heart, 
adipose tissue, and skeletal muscle.  As GLUT4 is the major glucose transporter for 
peripheral insulin stimulated glucose uptake, further evidence for the restriction of 
GLUT4 knock-out solely to the brain was that the rate of whole body glucose disposal 
was similar between NG4KO mice and littermate controls.  Further, tissue specific 
glucose uptake in adipose tissue and skeletal muscle was normal in NG4KO mice. 
 An interesting finding in this study was the expression of nestin-Cre alone 
resulted in a mild reduction in body weight and crown-rump length, consistent with 
preliminary results from other labs (B.B. Lowell and B.B. Kahn, personal 
communication).   As NG4KO and littermate Cre mice had no difference in body weight, 
neuronal GLUT4 deletion was concluded not to have an effect on overall body weight.  
Because of this effect of nestin-Cre expression, all experiments included WT, Lox, and 
Cre littermates as the 3 control groups to be compared to the NG4KO mice.  Notably, Cre 
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mice had similar metabolic phenotypes to WT and Lox mice in all other metabolic 
parameters assessed such as blood glucose levels, insulin levels, glucose tolerance, 
insulin sensitivity, and counterregulatory responses.  Thus, although nestin-Cre 
expression resulted in slightly decreased size, it did not affect any other metabolic 
phenotypes. 
 Fasting and fed glucose levels were similar in NG4KO mice and littermate 
controls, suggesting a lack of effect of neuronal GLUT4 on basal glucose homeostasis.  
Interestingly, female NG4KO mice had mild hyperinsulinemia in the fed state although 
no difference in fasted insulin levels were observed.  This hyperinsulinemia may be 
indicative of mild insulin resistance, characteristic of a pre-diabetic state.  When 
challenged with a glucose load during an intraperitoneal glucose tolerance test, male 
NG4KO had significantly higher blood glucose levels than littermate controls.  NG4KO 
female mice did not demonstrate glucose intolerance.  The gender specific difference was 
not surprising as other studies have observed phenotypes more pronounced in one sex 
than the other (36).  For example, in neuronal specific insulin receptor knock-out mice 
(NIRKO), on a standard chow diet, female NIRKO mice had increased food intake and 
body weight compared to controls, while male NIRKO mice and controls had similar 
food intake and body weight.  When an insulin tolerance test was performed, 
surprisingly, no difference in blood glucose was observed between male NG4KO and 
their littermate controls.  The impaired glucose tolerance but seemingly normal insulin 
sensitivity was initially speculated to be attributed to a pancreatic β-cell secretory defect.  
However, glucose stimulated insulin secretion was measured and no difference in insulin 
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levels were seen between NG4KO and littermate controls after a glucose load.  Thus, 
pancreatic β-cell function was intact and not affected by neuronal GLUT4 deletion.   
 An insulin tolerance test is an inexact measure of insulin sensitivity because 
several factors could confound interpretation of the results, including differences in 
counterregulatory responses.  As discussed below, NG4KO had an attenuated CRR to 
hypoglycemia and this impairment may have masked any differences in insulin 
sensitivity present in NG4KO mice.  To directly assess insulin sensitivity, the ―gold 
standard‖ hyperinsulinemic-euglycemic clamps was performed in NG4KO mice and 
control mice.  In the setting of carefully matched blood glucose levels, NG4KO mice 
required a significantly lower glucose infusion rate to maintain euglycemia than 
littermate controls, indicating insulin resistance.  To better define the exact nature of the 
insulin resistance, glucose fluxes and glucose uptake into specific tissues were measured 
during the euglycemic clamp.  Consistent with normal GLUT4 expression in peripheral 
tissues, NG4KO had a similar rate of glucose disposal (Rd) to littermate controls.  
Further, skeletal muscle and adipose tissue specific glucose uptake was not different 
between NG4KO and control mice.  Interestingly, the ability of insulin to suppress 
hepatic glucose production (HGP) was significantly impaired in NG4KO mice.  Thus, the 
insulin resistance in NG4KO mice is attributed to hepatic insulin resistance.  This data is 
of particular interest as previous studies have shown that central insulin signaling is 
crucial for insulin’s ability to fully suppress HGP (98;99).  One possibility for the altered 
hepatic insulin sensitivity is that insulin action in the central nervous system requires 
central GLUT4 to suppress HGP.  The absence of neuronal GLUT4 may prevent central 
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insulin from exerting its effects on HGP.  More direct studies to understand this 
relationship between CNS GLUT4 and insulin are warranted.    
 As GLUT4 and insulin receptors are coexpressed in up to 75% of key glucose 
sensing neurons in the ventromedial hypothalamus (15), brain GLUT4 may have a 
particular role in the ability of neurons to sense and respond to changes in glucose levels.  
To test this possibility, the counterregulatory response to hypoglycemia (CRR) was 
assessed in animals that had central GLUT4 inhibited pharmacologically (by indinavir) or 
genetically (NG4KO mice).  Indinavir has been shown to selectively inhibit glucose 
transport through GLUT4 in both cell culture and in brain slices (94-96).  Both 
pharmacologic inhibition and genetic deletion of brain GLUT4 resulted in significantly 
attenuated CRR.  Specifically, both approaches resulted in impaired epinephrine response 
as well as an attenuated glucagon response to hypoglycemia.  Interestingly, consistent 
with the observation that brain GLUT4 is important in the counterregulatory response to 
hypoglycemia, streptozotocin diabetic rats that have reduced GLUT4 expression in the 
brain (34) also have an impaired epinephrine and glucagon responses to hypoglycemia 
(100;101).   As with central insulin signaling, neuronal GLUT4 also has an important role 
in the CRR.   
 To determine whether this impaired CRR was unique to hypoglycemia or a result 
of a more global impairment in the sympathoadrenal response to stress in general, 
NG4KO mice and littermate controls were subjected to heat stress.  The adrenomedullary 
response to heat stress were identical in NG4KO and littermate control mice, indicating 
that NG4KO have an intact sympathoadrenal response to stress and that the impaired 
CRR response in NG4KO is unique to hypoglycemic stress.   
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 To determine whether the impaired CRR in the NG4KO mice was associated with 
impaired neuronal activation to hypoglycemia, c-fos activation was quantified in the PVN 
of mice that underwent a hyperinsulinemic hypoglycemic clamp (102;103).  In response 
to hypoglycemia, c-fos expression increased predominantly in the PVN but not in the 
VMH, consistent with previous studies (104).  Notably, PVN c-fos activation to 
hypoglycemia was significantly reduced in NG4KO mice compared to controls.  The 
impaired hypoglycemia-induced impaired c-fos activation in NG4KO mice could 
represent reduced glucose sensing of PVN neurons.  Alternatively, given that the PVN 
receives input from other glucose sensing neurons in other regions of the brain (i.e. the 
VMH), could represent an indirect reduction in afferent inputs from other brain regions.  
In either case, NG4KO had a profound impairment in c-fos activation, consistent with 
other models of impaired glucose sensing and impaired counterregulation (102;103).   
 To determine whether the impaired CRR and neuronal activation to hypoglycemia 
was associated with altered glucose uptake, brain glucose uptake was measured in 
NG4KO and littermate controls during a hyperinsulinemic hypoglycemic clamp.  No 
difference in regional brain glucose uptake was observed between groups during the 
hypoglycemic clamp.  Further, brain glucose uptake was also measured during a 
hyperinsulinemic euglycemic clamp.  Again, no statistically significant difference in 
regional brain glucose uptake was observed between NG4KO and littermate control mice.  
To note, since brain GLUT4 expression is much lower than GLUT1 and GLUT3, it is 
likely that that majority of glucose uptake occurred through these glucose transporters, 
thus masking any subtle effect caused by GLUT4 deletion. Further, due to technical 
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limitations in the 
14
C 2-deoxyglucose autoradiograph technique, we cannot rule out an 
effect of GLUT4 deletion on glucose uptake in individual glucose sensing neurons.   
 As these studies demonstrated a novel role of neuronal GLUT4 in energy 
homeostasis, whether deletion of neuronal GLUT4 would have an impact on the 
susceptibility to diet induced obesity was investigated.  NG4KO mice and littermates 
were fed a high fat diet (HFD, 60% calories from fat) for 11 weeks.  No difference in 
body weight change was observed between NG4KO and littermates, demonstrating that 
neuronal GLUT4 deletion and altered glucosensing did not increase the risk of diet 
induced obesity. 
 Several studies have suggested a relationship between insulin action in the CNS 
and GLUT4 (15;34;88;94).  Specifically, as insulin stimulates GLUT4 translocation to 
the plasma membrane in the peripheral tissue, a similar phenomena may occur in the 
central nervous system (94).  This current study does not directly address the role of 
GLUT4 in modulating central insulin effects.  However, some similarities were observed 
with NG4KO mice and neuronal insulin receptor knock-out mice (NIRKO).  Both 
NG4KO and NIRKO mice were glucose intolerant and insulin resistant (36).  Further, 
both NG4KO mice and NIRKO mice had impaired epinephrine responses and impaired 
neuronal activation to hypoglycemia (38;39).  Thus, central GLUT4 may play a role in 
exerting CNS insulin effects in regards to those roles.  However, the metabolic 
phenotypes of NG4KO mice and NIRKO mice were not exactly the same.  NIRKO mice 
had increased body weight and increased risk of diet induced obesity whereas NG4KO 
mice did not (36).  NG4KO mice had an impaired glucagon response to hypoglycemia in 
addition to the impaired epinephrine response whereas NIRKO mice exhibited 
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impairment only in the epinephrine response (38).  These observations are not surprising 
as mice with either muscle or adipose specific knock-out of GLUT4 (26;28) have 
drastically different phenotypes compared to mice with muscle or adipose specific knock-
out of insulin receptor (105;106), respectively.  GLUT4 and proteins involved in insulin 
signaling are co-expressed in many but not all areas of the brain.  For example, there is a 
dissociation between GLUT4 expression and insulin related aminopeptidase (IRAP) 
expression in the cerebellum (94).  Further, insulin has a plethora of actions independent 
of the stimulation of glucose uptake (107).  Taken together, GLUT4 may be involved in 
exerting some but not all of central insulin effects. 
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CHAPTER 2.  PARADOXICALLY, HYPOTHALAMIC GLUCOSAMINE 
INFUSION REDUCES FOOD INTAKE AND LIMITS WEIGHT GAIN WHILE 
ENHANCING BRAIN INSULIN SENSITIVITY   
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ABSTRACT 
In patients with uncontrolled diabetes, high blood  sugar further worsens diabetes control 
by causing resistance to insulin action.  Chronic hyperglycemia increases glucose flux 
through the hexosamine biosynthetic pathway (HBP) and impairs insulin signaling. 
Glucosamine, a molecule which mimics hyperglycemia by directly entering the HBP, has 
similarly been shown to induce insulin resistance in peripheral tissues.  Knowing the 
importance of the brain in mediating systemic metabolism, chronic infusion of a high 
concentration of glucose or glucosamine into the mediobasal hypothalamus of the brain 
was hypothesized to induce hypothalamic insulin resistance and, consistent with other 
models of central insulin resistance, lead to increases in food intake and body weight.  To 
test this hypothesis, glucose (GLU), glucosamine (GLN) or mannitol (MAN), an osmotic 
control, were each infused bilaterally into the mediobasal hypothalami of 9 week old, 
male, Sprague-Dawley rats for 3 weeks.  Contrary to our original hypothesis, GLU-
treated and GLN-treated rats weighed significantly less than their respective MAN-
treated controls.  Further, food intake was significantly reduced in GLN-treated rats 
compared to controls.  The decrease in food intake occurred in the absence of changes in 
hypothalamic NPY or POMC expression.  Interestingly, GLN-treated rats had increased 
central insulin sensitivity as ICV infusion of insulin resulted in a 2-fold greater 
phosphorylation of Akt in GLN-treated rats compared to MAN controls.  This study 
demonstrates a novel nutrient sensing role for glucosamine and the hexosamine 
biosynthetic pathway in regulating brain insulin sensitivity, food intake, and body weight. 
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 INTRODUCTION 
Obesity and caloric excess are major predisposing factors in the development of insulin 
resistance and Type 2 diabetes (108;109).  Persistent overabundance of nutrients, such as 
glucose, can induce insulin resistance, a hallmark of Type 2 diabetes (44;110).  The 
precise mechanisms of how excessive glucose leads to peripheral insulin resistance are 
incompletely understood.  One mechanism is enhanced flux through the hexosamine 
biosynthetic pathway (HBP) and subsequent increase in protein glycosylation (40;111).  
Between 2-5% of glucose entering the cell enters the HBP (111), the end-product of 
which is uridyl diphosphate-N-acetylglucosamine (UDP-GlcNAc) (41;111) (Figure 18).  
UDP-GlcNAc can then be added to serine and threonine residues of proteins by O-linked 
N-acetylglucosamine transferase (OGT) (41;111) (Figure 18).  The addition of UDP-
GlcNAc, termed O-linked glycosylation (O-GlcNAc) is considered to be a measure of 
nutritional status (41;111;112) and excess O-GlcNAc leads to peripheral insulin 
resistance.  At a cellular level, excess nutrients and increased O-GlcNAc negatively 
regulate nutrient import into the cell.  In skeletal muscle and adipose tissue, incubation 
with high levels of glucose or glucosamine (a substrate that directly enters the HBP) 
increases O-GlcNAc and results in insulin-resistance and impaired insulin-stimulated 
glucose uptake (42;43;113). 
 In addition to systemic insulin resistance, perturbations of insulin signaling in the 
central nervous system have also been implicated in the pathogenesis of Type 2 diabetes 
(36;37).  Animals with insulin receptors (IR) knocked-out in the brain were hyperphagic, 
glucose intolerant, and insulin resistant—hallmarks in the development of Type 2 
diabetes (36;37).  Insulin receptors are discretely expressed in particular areas of the 
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brain, including the mediobasal hypothalamus (MBH).  The MBH is an important site for 
integrating hormonal and nutritional signals and modulating whole body energy 
homeostasis (114;115).  Targeted disruption of IR in the MBH increased food intake and 
increased fat mass, similar to the whole brain IR knockout mice (36;37).   Whether 
chronic exposure to hyperglycemia and increased O-GlcNAc in the mediobasal 
hypothalamus can induce hypothalamic insulin resistance and lead to hyperphagia has yet 
to be determined.  In the current experiments, infusion of glucose or glucosamine (which 
directly enters the HBP and increases O-GlcNAc) in the MBH was hypothesized to 
induce hypothalamic insulin resistance, leading to increased food intake and body weight 
gain.   
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METHODS AND PROCEDURES 
Animals care and surgical procedures.  Eight to nine week old male Sprague-
Dawley rats (Charles River Laboratories) were individually housed in a temperature and 
light controlled environment maintaining the animal’s diurnal cycle (12hrs light, 12hrs 
dark) and with an ad lib standard rat chow diet.  During the experimental protocol, body 
weight and food intake was measured twice a week for 3 weeks.  All studies were done in 
accordance with the Animal Studies Committee at the Washington University School of 
Medicine. 
Surgical procedures and hypothalamic infusions.  Animals were anesthetized 
with isofluorane and were implanted with microinjection cannulas.  Cannulas (Plastics 
One Inc, Roanoke, VA) were targeted to the mediobasal hypothalamus bilaterally  (2.6 
mm posterior to the bregma, + 2.0 mm lateral to midline at a 9 degree angle, cannula 
length 10.6 mm) and attached to low flow rate osmotic pumps (Alzet model 2ML4, 
Durect, Cupertino, CA).  In one set of studies, the osmotic pumps were filled with either 
glucose (Sigma-Aldrich) or the osmotic control mannitol (Sigma-Aldrich) for an infusion 
rate of 16.5 micromoles/hr.  In another set of studies, osmotic pumps were filled with 
glucosamine (Sigma-Aldrich) or the osmotic control mannitol which were infused at a 
lower concentration (0.12 micromoles/hr) than the glucose infusions because 
glucosamine is a more potent activator of the HBP and  pilot experiments determined that 
this dose of glucosamine achieved a physiologically relevant increase in protein 
glycosylation.   Osmotic pumps were buried subcutaneously on the back of the animals.  
A third cannula to be used later for acute intracerebroventricular insulin or aCSF 
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injections was implanted into the 3rd ventricle (0.24 mm anterior to the bregma, on the 
midline, at an angle of 9 degrees, cannula length 10.5 mm). 
Short-term glucosamine infusion.  Cannulas were implanted into the 3rd 
ventricle of 8 week old Sprague-Dawley rats.  After a week recovery, rats were fasted for 
24 hours.  One hour before the onset of the dark cycle, glucosamine or mannitol was 
slowly infused (0.1 μl/min) into the 3rd ventricle (2.8 micromoles/hr) and infusion 
continued for the duration of the experiment.  Rats were given food at the onset of the 
dark cycle, and food intake was measured at 2 and 4 hours afterwards. 
Insulin Tolerance Test.  Animals were fasted overnight and given an 
intraperitoneal (i.p.) injection of 0.60 U/kg regular human insulin (Lilly).  Tail vein 
glucose measurements were made immediately before injection and at 15 min intervals 
for 90 min after insulin administration. 
Central Insulin Sensitivity.  After 3 weeks of hypothalamic infusion of 
glucosamine or mannitol, insulin (15 mU) or aCSF was injected into the 3rd ventricle of 
overnight fasted rats.  Twenty minutes later, brains were harvested and rapidly frozen in 
liquid nitrogen.  Hypothalami were processed by western blot analysis to measure insulin 
mediated Akt phosphorylation. 
Western Blot.    Hypothalami were homogenized in buffer containing 1% Igepal 
(Sigma), 0.5%  sodium dodecyl sulfate (Sigma), 0.1 mM Phenylmethylsulfonyl fluoride 
(Sigma), 1X complete protease inhibitor (Sigma), 1 mM NaF (Sigma), and 1 mM 
Na3VO4 (Sigma) in phosphate buffered saline (pH=7.4), centrifuged at 14,000 rpm for 
30 min, and supernatant was collected.  Protein samples (200 µg) were then separated on 
12.5% Tris-HCl gel, transferred to nitrocellulose membrane (Bio-Rad), and were 
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immunoblotted with antibodies against phosphorylated Akt (1:400; Cell Signaling), total 
Akt (1:600; Cell Signaling), or beta-N-acetyl-D-glucosamine (O-GlcNAc) (1:1000; 
Covance). 
Brain stereotaxic punch biopsies of the arcuate nucleus and ventromedial 
hypothalamus.  After 3 weeks of bilateral hypothalamic infusion glucosamine or 
mannitol, brains were harvested and frozen in 2-methylbutane in dry ice at -20°C.  Brain 
sections (500 µm) were cut and collected using a Leica CM1850 cryostat (Leica 
Microsystems Inc., Bannockburn, IL).  According to a rat brain stereotaxic atlas (Paxinos 
and Watson), the arcuate nucleus (ARC) and ventromedial hypothalamus (VMH) were 
identified and punched out with a stainless steel needle. Punch biopsies were placed in 
Eppendorf tubes and stored at -80°C until real-time revere transcription polymerase chain 
reaction (RT-PCR) analysis.   
Real-time RT-PCR.  Punch biopsy total RNA was extracted with TriZOL 
(Invitrogen) and reversed transcribed to cDNA using Superscript (Invitrogen).  Real-time 
PCR reactions were prepared using SYBR® Green PCR Master Mix (Applied 
Biosystems), and reactions were carried out with ABI Prism® 7000 Sequence Detection 
(Applied Biosystems).  Primers for real-time PCR analysis are as follows:  rat NPY (F 5'-
GCCATGATGCTAGGTAACAAACG-3', R 5'-GTTTCATTTCCCATCACCACATG-
3'); rat POMC (F 5'-CCAGGCAACGGAGATGAAC-3', R 5'-
TCACTGGCCCTTCTTGTGC-3'); L32 (F 5'-TAAGCGAAACTGGCGGAAAC-3', R 5'-
TCATTTTCTTCGCTGCGTAGC-3'). 
Glucose, Insulin, and Leptin Measurements.  Tail vein blood samples were 
taken in overnight fasted rats one day prior to surgical implantation of cannulas and after 
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the 3 week infusion of hypothalamic infusions.  Blood glucose was measured by glucose 
oxidase method (B-D logic Glucometer).  Plasma insulin was measured by ultrasensitive 
rat insulin ELISA (Crystal Chem Inc., Downer’s Grove, IL), and plasma leptin was 
measured by leptin ELISA assay (Crystal Chem Inc.).     
Statistical Analysis.  Data are represented as mean + S.E.M.  Statistical analysis 
was performed using unpaired Student’s t test or two-way ANOVA, as indicated.  P 
<0.05 was considered statistically significant. 
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RESULTS 
Chronic hypothalamic infusion of glucose limited body weight gain.   
To determine whether chronic hyperglycemia in the central nervous system would 
induce central insulin resistance and affect whole body energy homeostasis, glucose was 
infused bilaterally into the mediobasal hypothalamus for 3 weeks.  Intriguingly, body 
weight was significantly lower in glucose-infused rats as compared to mannitol infused 
controls (P<0.05) (Figure 15A). No statistically significant difference in food intake was 
observed between groups (Figure 15B).   
 
Mediobasal glucosamine infusion increased hypothalamic protein glycosylation, 
reduced food intake, and limited body weight gain.  
Through the hexosamine biosynthetic pathway, glucose and glucosamine can 
increase protein glycosylation, leading to insulin resistance in peripheral tissues 
(40;42;112).  To assess the effect of enhanced flux through the HBP in the central 
nervous system, glucosamine or the osmotic control mannitol was infused into the 
mediobasal hypothalamus for 3 weeks and food intake and body weight were measured.   
As with the hypothalamic glucose infusions, glucosamine treatment resulted in 
rats weighing significantly less than controls during the infusion period (Figure 16C).  
Further, glucosamine infusion resulted in significantly reduced food intake (Figure 16D).  
At the end of the 3 week infusion, hypothalami were harvested.  As expected, 
hypothalamic protein glycosylation as measured by Western blot analysis using anti-O-
GlcNAc antibody was increased ~2-fold in glucosamine infused rats compared to 
mannitol controls (Figure 16).  Interestingly, the degree of hypothalamic protein 
glycosylation was inversely correlated with the change in body weight during the 
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infusion period (Figure 16C).  Specifically, increased protein glycosylation correlated 
with reduced body weight gain.  No significant difference was observed in fasting blood 
glucose, insulin, and leptin levels (Table 1). 
 
Central and peripheral insulin sensitivity is enhanced by glucosamine infusion.   
To test whether glucosamine could also affect insulin sensitivity in the central 
nervous system, at the end of the infusion period rats were fasted overnight, injected with 
intracerebroventricular (ICV) insulin (15 mU) or an equal volume of aCSF, and after 20 
minutes hypothalami were harvested and analyzed for insulin-induced Akt 
phosphorylation (pAkt).  Insulin induced Akt phosphorylation was significantly higher in 
glucosamine treated rats given ICV insulin compared to mannitol treated rats given ICV 
insulin (Figure 17).   
Additionally, an insulin tolerance test was performed in rats at the end of the 3 
week infusion period.  An intraperitoneal injection of insulin (0.60 U/kg) was given and 
blood glucose was measured immediately before injection and at 15 minute intervals for 
90 min.  Glucosamine treated rats had significantly lower blood glucose during the 
insulin tolerance test compared to controls (p < 0.05 by ANOVA) (Figure 17C).   
 
Alteration in food intake and body weight were independent of changes in 
neuropeptide expression.   
To determine whether the effects on food intake and body weight elicited by 
glucosamine are dependent on changes in neuropeptide expression, punch biopsies of the 
ventromedial hypothalamus (VMH) and arcuate nucleus (ARC) were taken from 
glucosamine and mannitol treated rats.  Real-time PCR analysis was performed to 
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measure neuropeptide Y (NPY) and pro-opiomelanocortin (POMC) expression.  No 
significant difference in NPY or POMC expression was observed between glucosamine 
and mannitol treated animals in either the VMH or ARC (Figure 17D and Figure 17E). 
 
Short-term glucosamine infusion does not alter food intake. 
In a separate study, to determine whether glucosamine can also acutely affect food intake, 
glucosamine or mannitol was continuously infused into the 3rd ventricle of 24 hour 
fasted rats 1 hour prior to the onset of the dark cycle till the end of the refeeding study.  
Rats were given food at the onset of the dark cycle and food intake was measured at 2 
and 4 hours later.   No significant difference in food intake was observed between groups 
(Figure 15E). 
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Figure 15.  Chronic hypothalamic glucose infusion reduced body weight while 
hypothalamic glucosamine infusion reduced body weight and food intake.  (A)  
Chronic hypothalamic glucose infusion (closed circles, n=9) significantly reduced the 
body weight gain compared to rats receiving hypothalamic mannitol (osmotic control) 
infusion (open circles, n=9).  (B)  Food intake was similar between glucose infused 
(closed circle) and mannitol infused (open circle) rats.  (C) Consistent with hypothalamic 
glucose infusion, three weeks of glucosamine infusion (closed circles, n=22) resulted in 
lower body weight compared to mannitol controls (open circles, n=19).  (D)  
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Hypothalamic glucosamine infusion (closed circles) also significantly decreased food 
intake compared to mannitol controls (open circles). (E)  To test the acute effects of 
glucosamine infusion, glucosamine (black bars, n=6) or mannitol (white bars, n=7) was 
infused into the third ventricle of 24 hour fasted rats 1 hour prior to the onset of the dark 
cycle till the end of the refeeding study.  Rats were then given food at the onset of the 
dark cycle.  No significant difference in food intake was observed at 2 or 4 hours after the 
introduction of food.  # P < 0.05 versus mannitol by ANOVA.  * P < 0.01, compared to 
mannitol by ANOVA.   
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Figure 16.  Mediobasal hypothalamic glucosamine infusion increased hypothalamic 
protein glycosylation.  (A) Representative western blot analysis using anti-GlcNAc 
antibody.  Overall protein glycosylation in the hypothalamus was increased after 3 weeks 
of glucosamine infusion compared to mannitol infused controls.  Molecular marker 
weights are indicated with numbers on the left.  (B)  Quantification of western blots.  
Glucosamine infusion (black bar, n=14) increased hypothalamic glycosylation over 2-
fold (385±112 vs 187±34 densitometric units) compared to mannitol controls (white bar, 
n=9).  (C)  Hypothalamic protein glycosylation inversely correlated with the change in 
body weight at the end of the 3 week infusions (R=0.74, P < 0.001; n=23).  Increased 
hypothalamic protein glycosylation correlated with lower body weight change.  * P<0.05, 
compared to mannitol. 
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Mannitol Glucosamine 
Basal Post-infusion Basal Post-infusion 
Glucose (mg/dl) 91 +6 87 +4 91+3 97+4 
Insulin (pg/ml) 0.57+ 0.31 0.59+0.16 0.34+0.08 0.36+0.16 
Leptin (pg/ml) 1052+148 1764+350 800+127 1182+252 
 
 
Table 1.  Metabolic Profile of mediobasal hypothalamic mannitol and glucosamine 
infused rats.  Glucosamine infusion did not affect fasting glucose (n=19-22 per group), 
insulin (n=7-10 per group) and leptin levels (n=7-10 per group) compared to mannitol-
treated animals.  Data represents + S.E.M. 
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Figure 17.  Hypothalamic glucosamine infusion enhanced both central and 
peripheral insulin sensitivity.  (A)  Representative Western blot of insulin stimulated 
phosphorylation of Akt (pAkt) in the hypothalamus.  Insulin (15 mU) or aCSF was 
microinjected into the 3
rd
 ventricle of overnight fasted rats.  After 20 min, hypothalami 
were harvested and processed for western blot analysis.  (B)  Quantification of insulin-
stimulated Akt phosphorylation in the hypothalamus.  In response to 3
rd
 ventricle insulin 
infusion, glucosamine treated rats (black bars, n=6) had significantly enhanced 
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phosphorylation of Akt (pAkt) compared to mannitol treated rats (white bar, n=4) while 
total Akt was unaffected.  No significant difference in pAkt or total Akt levels was 
observed between glucosamine (black bars, n=7) or mannitol (white bars, n=4) treated 
rats receiving 3
rd
 ventricle aCSF injection.  (B) Insulin tolerance test (ITT) after 3 weeks 
of glucosamine (closed circles, n=8) or mannitol (open circles, n=8) infusion.  Animals 
were injected intraperitoneally with 0.6 U/kg of insulin, and glucose was measured 
immediately before injection and at 15 min intervals.  (D and E)  There was no 
significant difference in NPY or POMC expression between glucosamine (black bar, 
n=9) and mannitol (white bar, n=8) treated rats in either the arcuate nucleus (D) or in the 
ventromedial hypothalamus (E),    * P < 0.05 compared to mannitol + ICV insulin; 
#
P < 
0.05 vs. mannitol by ANOVA. 
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Figure 18.  Model of hypothalamic glucose and glucosamine infusion effects on 
whole body metabolism.  As glucose enters this cell in the hypothalamus, 2-5% of 
glucose flux enters the hexosamine biosynthetic pathway (HBP), ultimately leading to 
increased levels of uridyl diphosphate-N-acetylglucosamine (UDP-GlcNAc).  
Glucosamine directly enters the HBP and also increases UDP-GlcNAc levels.  UDP-
GlcNAc is then attached to proteins, increasing overall protein glycosylation.  In this 
study, increased hypothalamic protein glycosylation led to increased hypothalamic 
insulin sensitivity, decreased food intake, decreased body weight, and enhanced 
peripheral insulin sensitivity. 
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DISCUSSION 
Hyperglycemia and increased flux through the hexosamine biosynthetic pathway induces 
insulin resistance in adipose tissue and skeletal muscle.  In these studies, we tested the 
hypothesis that chronic infusion of glucose or glucosamine, a molecule that directly 
enters the HBP, into the hypothalamus would similarly induce central insulin resistance 
leading to obesity and hyperphagia.  Contrary to our original hypothesis, hypothalamic 
glucose and glucosamine infusion reduced body weight while glucosamine infusion also 
reduced food intake and enhanced both central and peripheral insulin sensitivities.  Our 
findings suggest a novel central nutrient sensing mechanism in which sugar flux through 
the hexosamine biosynthetic pathway can modulate food intake and body weight. 
Contrary to our initial hypothesis, central glucose infusion resulted in rats 
weighing less than controls.  Surprisingly, food intake was not altered despite a reduction 
in body weight.  However, several studies have observed that changes in central nervous 
system (specifically within the hypothalamus) can result in alterations to whole body 
metabolism and body weight that may be independent of food intake (116-118).  In a 
similar fashion, chronic glucose infusion into the mediobasal hypothalamus affected body 
weight without altering food intake. 
One possible mechanism in which hypothalamic glucose infusion modulated body 
weight is increased flux through the hexosamine biosynthetic pathway (HBP).   To 
determine whether the HBP in the hypothalamus could modulate whole body energy 
homeostasis, glucosamine, a molecule that directly enters the HBP pathway (Figure 18), 
was continuously infused into the mediobasal hypothalamus for three weeks.  
Interestingly, and consistent with the chronic high glucose infusion study, hypothalamic 
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glucosamine infusion also resulted in a reduction in body weight gain of a similar 
magnitude.  Hypothalamic glucosamine infusion reduced food intake and reduced body 
weight as compared to control rats.  Consistent with the reduced body weight, plasma 
leptin levels tended to be lower in glucosamine infused animals, although not statistically 
significant between groups.  Systemic glucose and insulin levels were not different 
between treatment groups although the insulin tolerance test did demonstrate that the 
glucosamine treated rats were more insulin sensitive that controls (Figure 17C).  
Presumably, the reduced body weight in the glucosamine infused animals (Figure 15) 
accounted for the improvement in systemic insulin sensitivity, but it is possible that the 
enhanced hypothalamic insulin sensitivity (Figure 17A) may have directly contributed to 
the enhance peripheral insulin sensitivity (119).   
Although antithetical to our tested hypothesis, these initially paradoxical findings 
support the notion that increased flux through the HBP acts as a nutrient sensor 
(41;111;112).  Enhanced flux into the HBP is thought to signal nutrient excess 
(41;111;112).  In peripheral tissues, increased HBP flux may lead to insulin resistance 
and thus limiting substrates (i.e. glucose) from entering the cell (41;112).  In the same 
regard, increased metabolism through the HBP in the hypothalamus could signal nutrient 
surfeit and would lead to a suppression of food intake and, consequently, body weight.   
Indeed, previous studies have demonstrated that glucosamine can increase expression of 
satiety signals.  Incubation of adipocytes with glucosamine resulted in increased 
expression of the anorexigenic hormone leptin (120).  Further, the significant inverse 
correlation between the extent of hypothalamic protein glycosylation and body weight 
supports the evidence that increased HBP flux acts as a nutrient sensor.  Indeed, 
60 
 
consistent with these findings are the observations that the degree of brain protein 
glycosylation changes with physiological changes in nutritional status, (e.g., fasting 
results in decreased brain glycosylation) (120;121). These data support the notion that 
protein glycosylation within the brain acts as a nutrient sensor, or acts to modify nutrient 
sensing in the hypothalamus, and thus modulates overall energy homeostasis. 
Studies in pancreatic β-cells further support the concept that protein glycosylation 
via the HBP acts as a nutrient sensor.  Increased protein glycosylation by transgenic 
overexpression of OGT leads to enhanced glucose-stimulated insulin secretion (46).  
Reduction of protein glycosylation by pharmacological inhibition of glutamine:fructose-
6-phosphate amidotransferase (GFAT) or targeted disruption of OGT by siRNA resulted 
in reduced glucose-stimulated insulin secretion in isolated pancreatic β-cells (122;123).  
Thus, the HBP and protein glycosylation in the β-cell modulates glucose sensing and 
insulin secretion. 
To determine whether glucosamine can acutely affect food intake, glucosamine or 
the osmotic control mannitol was infused into the third ventricle of 24 hour fasted rats.  
Glucosamine or mannitol was infused one hour prior to the onset of the dark cycle.  Food 
was then provided at the onset of the dark cycle, and food intake was measured at 2 and 4 
hours afterwards.  No difference in food intake was observed between groups. This result 
is not surprising as many of the enzymes important in glycosylation, such as OGT, are 
highly expressed in the nucleus (40;41).  Thus many of the effects of hypothalamic 
glucosamine infusion on whole body energy homeostasis may first depend on changes in 
gene expression and subsequent translation to protein synthesis instead of acutely 
modulating phosphorylation and signaling of various proteins and enzymes. This data is 
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consistent with the observation that a difference in body weight and food intake in 
glucosamine infused rats was delayed and not observed until the second week of 
hypothalamic infusions (Figure 15).  Importantly, these results demonstrate that 
glucosamine does not act as a noxious stimulus to adversely affect short term food intake.       
A possible mechanism for glucosamine’s anorexigenic effects was its effect on 
central insulin signaling.  Mediobasal hypothalamic infusion of glucosamine enhanced 
hypothalamic insulin sensitivity.  Insulin has anorexigenic effects centrally (124-126), 
and the reduced food intake and body weight could be attributed to increased central 
insulin sensitivity.  Intriguingly, expression of neuropeptide Y (NPY) and 
proopiomelanocortin (POMC), the major hypothalamic orexigenic and anorexigenic 
neuropeptides (115), were not affect by glucosamine infusion.  Although the 
anorexigenic effect of hypothalamic insulin signal is thought to be mediated by reciprocal 
changes in hypothalamic NPY and POMC expression (127;128), the absence in changes 
in neuropeptide expression in these experiments point to the intriguing possibility that 
alternative mechanisms exist by which enhanced flux through HBP and/or enhanced 
insulin signaling act to reduce food intake and body weight 
These data provide evidence of a novel nutrient sensing system in the 
hypothalamus.  Enhanced metabolism through the HBP may increase O-GlcNAc, which 
in turn, leads to an activation of satiety signals (Figure 18).  O-GlcNAc can interact with 
several signaling molecules and modulate gene transcription (40;111), though the exact 
targets of O-GlcNAc that lead to attenuation of food intake and body weight are still 
unknown and are currently being investigated.  The HBP may become a potential 
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therapeutic target to modulate food intake and body weight and, hence, combat the ever-
growing epidemic of obesity and diabetes.    
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CHAPTER 3.  RECURRENT, MODERATE HYPOGLYCEMIA AMELIORATES 
BRAIN DAMAGE AND COGNITIVE DYSFUNCTION INDUCED BY SEVERE 
HYPOGLYCEMIA 
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ABSTRACT  
 Although intensive glycemic control achieved with insulin therapy increases the 
incidence of both moderate and severe hypoglycemia, the extent to which severe 
hypoglycemia causes brain damage and cognitive impairments continues to be 
unresolved.  It was hypothesized that recurrent moderate hypoglycemia might 
―precondition‖ the brain and protect the brain against damage caused by severe 
hypoglycemia. To test this hypothesis, nine-week old male Sprague-Dawley rats were 
subjected to either three consecutive days of recurrent, moderate (25-40 mg/dl) 
hypoglycemia (RH) or saline injections.  On the fourth day, rats were subjected to a 
hyperinsulinemic (0.2 U/kg/min) severe hypoglycemic (~11 mg/dl) clamp for 60 or 90 
minutes.  Neuronal damage was subsequently assessed by H&E and Fluoro-Jade B 
staining.  The functional significance of severe hypoglycemia induced brain damage was 
evaluated by motor and cognitive testing. The results demonstrated that following severe 
hypoglycemia, RH pretreated rats had 62-74% less brain cell death and significantly 
reduced deficits in cognitive performance.  In summary, antecedent recurrent moderate 
hypoglycemia ―preconditioned‖ the brain and markedly limited both the extent of severe 
hypoglycemia induced neuronal damage and cognitive impairment.  In conclusion, 
changes brought about by recurrent moderate hypoglycemia can be viewed, 
paradoxically, as providing a beneficial adaptive response in that there is mitigation 
against severe hypoglycemia induced brain damage and cognitive dysfunction.   
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INTRODUCTION 
Hypoglycemia is the major obstacle in achieving tight glycemic control in people 
with diabetes (129).  Intensive insulin therapy increases the risk of iatrogenic 
hypoglycemia (49).  Episodes of both moderate and severe hypoglycemia have long-term 
clinical consequences. Recurrent moderate hypoglycemia induces a maladaptive response 
that limits symptoms of hypoglycemia (hypoglycemia unawareness) and limits the 
counterregulatory response to subsequent hypoglycemia (hypoglycemia associated 
autonomic failure – HAAF) and thus jeopardizes patient safety (82;129).  By depriving 
the brain of glucose, more severe hypoglycemia has been shown to cause brain damage in 
animal studies.  Severe hypoglycemia induced damage, especially in the hippocampus, 
leads to long-term impairments in learning and memory (54;130).  However, studies 
examining the effect of severe hypoglycemia in humans have been conflicting.  Severe 
hypoglycemia alters brain structure (64;131) and causes significant cognitive damage in 
many (56-66) but not all (67-72) studies.  Reasons for the discrepancy between human 
and animal studies are unknown but a major contributing factor may be the extent of 
glycemic control (including recurrent hypoglycemia) prior to the episode of severe 
hypoglycemia.   
In other models of brain damage, such as a stroke, it has been shown that brief, 
mild episodes of antecedent brain ischemia causes a beneficial adaptation that serves to 
protect the brain against a subsequent episode of more severe ischemia (a phenomena 
known as ischemic pre-conditioning) (76).  In a similar fashion, it was hypothesized that 
antecedent, recurrent episodes of moderate hypoglycemia could protect the brain against 
damage caused by a subsequent episode of severe hypoglycemia. 
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 To investigate this hypothesis, recurrent moderately hypoglycemic (25-40 mg/dl) 
rats and recurrent saline injected rats were subjected to hyperinsulinemic, severe 
hypoglycemic clamps (10-15 mg/dl).  The rats were either sacrificed one week after the 
severe hypoglycemia to quantify brain damage or were evaluated by behavioral and 
cognitive tests 6-8 weeks after the episode of severe hypoglycemia.  The results indicate 
that recurrent antecedent moderate hypoglycemia acts to ―precondition‖ the brain and 
protect it against neurological damage and cognitive defects induced by a single episode 
of severe hypoglycemia.   
67 
 
RESEARCH DESIGN AND METHODS 
Animals.  Nine week old male Sprague-Dawley rats (Charles River Laboratories) 
were individually housed in a temperature and light controlled environment maintaining 
the animal’s diurnal cycle (12hrs light, 12hrs dark) and with an ad lib standard rat chow 
diet.  All studies were done in accordance with the Animal Studies Committee at the 
Washington University School of Medicine.  
Implantation of arterial and venous catheters.  Rats were anesthetized with an 
intraperitoneal injection of Ketamine 87 mg/kg and Xylazine 2.6 mg/kg.  A micro-
renathane® (Braintree Scientific, Boston, MA) catheter was inserted into the left carotid 
artery and two catheters were implanted into the right jugular vein.  To maintain patency, 
catheters were filled with a 40% polyvinylpyrrolidone (Sigma) in heparin (1000 USP 
U/ml) solution (Baxter Healthcare Corporation, Deerfield, IL). 
 Recurrent Moderate Hypoglycemia.  One week after catheter implantation, 
non-fasted rats were injected with subcutaneous regular human insulin (RH) [6 U/kg on 
day 1; 5 U/kg on day 2; and 4 U/kg on day 3] (Lilly, Indianapolis, IN) while the control 
group (CON) were given injections of equal volume saline for three consecutive days.  
Food was withheld and tail vein blood samples were obtained hourly in both treatment 
groups.  For insulin treated rats, blood glucose ranged between 25-40 mg/dl for three 
hours.  Hypoglycemia was terminated after three hours by a subcutaneous injection of 
dextrose (Hospira, Lake Forest, IL), and the rats were then allowed free access to food.   
Hyperinsulinemic-Severe Hypoglycemia Clamp.  Animals were fasted 
overnight after the third day of injections.  The following morning, vascular catheters 
were externalized for the hyperinsulinemic (0.2 U/kg/min) severe hypoglycemic clamp.  
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Rats were awake, unrestrained, and had free access to water.  Arterial blood samples 
were obtained every 15 minutes to measure blood glucose using Ascensia Contour blood 
glucose monitors (Bayer HealthCare, LLC, Mishawaka, IN).  Follow basal sampling, 
insulin was infused intravenously and glucose was co-infused.  The target for severe 
hypoglycemia was glucose levels of 10-15 mg/dl, as this level of hypoglycemia was 
necessary to induce neuronal damage (130;132).  Once the blood glucose dropped to 
below 15 mg/dl, the clock was re-set and severe hypoglycemia was maintained at 10-15 
mg/dl by adjusting the rate of continuous intravenous glucose infusion.  This technique 
allowed both groups to be precisely matched for duration and depth of hypoglycemia in 
unrestrained animals, without the confounding effects of anesthesia.  Blood glucose was 
maintained below 15 mg/dl for either 60 minutes (CON-SH60, n=6; RH-SH60, n=10) or 
90 minutes (CON-SH90, n=20; RH-SH90, n=18) (Figure 2A and 3A).  To terminate 
hypoglycemia, insulin infusion was ceased and animals were given infusions of dextrose 
until they could maintain normal blood glucose values without dextrose infusion.  Blood 
samples were taken during the basal period and 30 min into the severe hypoglycemia for 
epinephrine measurements, as determined by a single isotope derivative (radioenzymatic) 
method (97). 
 Episodes of seizure-like behavior were noted during the severe hypoglycemic 
clamps.  Tonic-clonic seizure-like behavior was visually noted by characteristic brief (5-
10 seconds) of neck extensions, tonic stretching, uncontrolled limb movements, and 
spontaneous spinning (132;133).  The number of episodes of seizure-like behavior was 
quantified for each rat during the clamp period and was later correlated with histological 
and behavioral findings. 
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 To provide additional groups of experimental control rats not exposed to severe 
hypoglycemia, two more groups of rats were made either recurrently hypoglycemic or 
given saline injections, as described above, and on the fourth day, instead of a severe 
hypoglycemic clamp, the rats underwent a 90 minute hyperinsulinemic (0.2 U/kg/min) 
euglycemic clamp with blood glucose maintained above 70 mg/dl (CON-EUG, n=9; RH-
EUG, n=11).  These two groups served as control rats treated in the same fashion except 
that they were not exposed to severe hypoglycemia.   
 Rats exposed to severe hypoglycemia and euglycemic controls were subsequently 
analyzed either for brain damage or subjected to tests of sensorimotor and cognitive 
function (Figure 19).  
Histology.  Rats exposed to severe hypoglycemia and euglycemic controls were 
anesthetized with isofluorane one week after their clamp and intracardially perfused with 
0.01 M PBS (Sigma, Saint Louis, MO) followed by 4% paraformaldehyde (Electron 
Microscopy Sciences, Hatfield, PA).  The brains were immersed in 4% paraformaldehyde 
overnight and then cryoprotected in 30% sucrose.  Beginning at 2.8 mm posterior to the 
bregma, coronal cryostat sections (20 μm) were collected and mounted on superfrost 
coated slides (VWR, West Chester, PA).  Four coronal sections, 120 μm apart, were then 
analyzed for neuronal damage by Fluoro-Jade B (Chemicon International, Inc., CA) and 
hematoxylin and eosin (H&E, Sigma, St. Louis, MO) staining, according to 
manufacturer’s protocol.  Fluoro-Jade B (FJB) is a well characterized stain for 
degenerating neurons (134).  The number of fluorescent cells (Fluoro-Jade positive cells) 
was counted in both hemispheres of the cortex and of the hippocampal structures, CA1 
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and dentate gyrus.  For each region of interest, data is expressed as the average number of 
Fluoro-Jade B positive (FJB+) cells per section. (CON-SH90, n=9; RH-SH90, n=8). 
Behavioral Testing.  Rats were given 6-8 weeks to recover from the 
hyperinsulinemic hypoglycemic (CON-SH90, n=11; RH-SH90, 9) and hyperinsulinemic 
euglycemic clamp (CON-EUG, n=7; RH-EUG, n=9), at which time they were moved to 
the behavioral testing facility and allowed one week to acclimate to the new environment.  
To determine if severe hypoglycemia produced long-term deficits in general activity level 
or sensorimotor function, (which could have confounded interpretation of cognitive test 
performance) the rats were evaluated on a 1-h locomotor activity test and on a battery of 
sensorimotor measures, as described below. Following these assessments, they were 
tested on the Morris water maze task to determine their spatial learning and memory 
capabilities. 
1-h Locomotor activity test and sensorimotor battery. General locomotor activity 
and exploratory behavior were evaluated over a 1-hr period using a computerized system 
(MotorMonitor, Kinder Scientific, LLC, Poway, CA) of photobeam pairs to separately 
quantify ambulations (whole body movements) and rearing frequency. To determine if 
severe hypoglycemia produced sensorimotor disturbances, a set of tests was conducted to 
measure balance, strength, coordination and initiation of movement using the ledge, 
platform, 90
o
 inclined screen, and walking initiation tests, as previously described (135). 
Water maze cognitive testing.  Spatial learning and memory were assessed using 
the Morris water maze test utilizing general procedures similar to previously-published 
methods (135).  A computerized tracking program (Polytrack, San Diego Instruments, 
San Diego, CA) was used to record the swim path lengths and time required to find the 
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platform. The cued condition involved conducting two sessions of three trials each (60-s 
maximum/trial) per day for two consecutive days where the rats were trained to swim to 
the submerged platform (1.5 cm below the surface) marked (cued) by a visible pole with 
3 h intervening between sessions.  The data were analyzed in blocks of three trials each 
for a total of four blocks. Three days later, the spatial learning capabilities of the rats 
were tested using the place condition in the water maze. This is a reference-memory 
based task where the rats were trained to learn the position of a submerged and non-
visible (since pole is removed) platform which remained in the same location across all 
trials. The place trials protocol involved conducting two sessions of 3 trials each (60-s 
maximum) per day for five consecutive days using a 3-h interval between sessions. The 
data were analyzed in blocks of six trials each (two daily sessions) for a total of 5 blocks. 
On day 5, a probe trial was conducted 1 h after the last place trial which involved 
removing the platform from the pool and quantifying rats' search behaviors in the four 
pool quadrants for 30 s to evaluate retention of the platform location. Probe trial 
performance variables included: the number of times a rat passed directly over the 
platform location (platform crossings); the time spent in the target quadrant versus the 
time spent in each of the other pool quadrants (spatial bias), and average proximity 
(distance to the platform location sampled and averaged across 1-s epochs throughout the 
trial).  
Statistical Analysis.  All data are expressed as mean ± SEM, and were by either 
Student t-tests or analysis of variance (ANOVA) models.  Quantification of brain damage 
and behavioral assessments were made by investigators blinded to treatment conditions. 
The behavioral data were analyzed by a two way ANOVA assessing variables of group 
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(severe hypoglycemia vs euglycemia) and treatment (recurrent hypoglycemia or saline 
injections).  Where appropriate, ANOVA models also included one within-subjects 
(repeated measures) variable such as Blocks of Trials, and Huynh-Feldt correction was 
used for all within-subjects effects containing more than two levels. When multiple 
comparisons were conducted, Bonferroni correction was used to help maintain prescribed 
alpha levels (e.g., 0.05). 
73 
 
RESULTS 
Recurrent hypoglycemia reduced cortical brain damage induced by 60 min of severe 
hypoglycemia.  To examine whether prior episodes of moderate hypoglycemia reduce 
susceptibility to severe hypoglycemia-induced brain damage, rats were treated with three 
days of insulin injections to induce moderate hypoglycemia (RH) or given control saline 
(CON) injections.  On the fourth day, severe hypoglycemia was induced in awake, 
unrestrained animals in both treatment groups using a hyperinsulinemic severe 
hypoglycemic clamp.  To verify that the recurrent moderate hypoglycemia recapitulated 
the syndrome of hypoglycemia associated autonomic failure (HAAF), epinephrine levels 
were measured before and during the hypoglycemic clamp.  As expected, recurrently 
hypoglycemic rats exposed to 60 minute of severe hypoglycemia (RH-SH60) had a 
significantly impaired epinephrine response compared to control saline injected rats 
exposed to 60 minutes of severe hypoglycemia (CON-SH60) (2001+241 and 3487 +474 
pg/ml, p < 0.01) (Figure 20B). 
No significant difference in blood glucose was observed before, during, or after 
the 60 min severe hypoglycemic clamps between RH and CON rats (Figure 20A).  
During the 60 min of severe hypoglycemia, blood glucose was precisely maintained 
between 10-15 mg/dl for 60 min (RH-SH60:12.7 + 0.9 and CON-SH60: 12.6 + 0.5 mg/dl, 
p=NS).  One hour after the clamp, blood glucose was not significantly different between 
groups (RH-SH60: 81 +19 and CON-SH60: 90 +15 mg/dl, p=NS) (Figure 20A).  
   Recurrent hypoglycemic treated rats had 64% less neuronal damage, as assessed 
by the number of Fluoro-Jade B positive (FJB+) cells, in the cortex than controls (173 + 
64 vs. 479 + 170 cells, p<0.05) (Figure 20C and Figure 20D).  It was noted that 60 min of 
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severe hypoglycemia did not induce significant damage in the hippocampus in either RH-
SH60 or CON-SH60.    
 
Recurrent hypoglycemia attenuated cortical and hippocampal brain injury after 90 
minutes of severe hypoglycemia.  To more consistently induce hypoglycemic brain 
damage in the hippocampus, the above experiments were repeated except that the 
duration of severe hypoglycemia was extended to 90 min.  The average blood glucose 
during 90 min of severe hypoglycemia was 10.9+0.2 versus 11.0+0.3 mg/dl in the saline 
injected (CON-SH90) and recurrently hypoglycemic (RH-SH 90) rats, respectively 
(p=NS) (Figure 21A).  As an additional set of experimental controls, euglycemic 
hyperinsulinemic clamps were also performed in recurrently hypoglycemic (RH-EUG) or 
saline injected control (CON-EUG) rats.  Notably, in these euglycemic control groups, 
blood glucose was maintained on average at 76+5 and 84+6 mg/dl in the CON-EUG and 
RH-EUG, respectively (p=NS) (Figure 21A).   
Again validating the model of HAAF, recurrent hypoglycemia resulted in the 
expected impairment of the epinephrine response to hypoglycemia (CON-SH90: 
3175+516 and RH-SH90: 2077+426 pg/ml, p<0.05) (Figure 21B).   Severe hypoglycemia 
of 90 min induced significant cellular damage in the cortex, as evidenced by the presence 
of pyknotic cells observed with H&E staining (Figure 22A) and the marked number of 
fluorescent cells with Fluoro-Jade B staining (Figure 22B).  Interestingly, 90 min of 
severe hypoglycemia induced 6-fold greater cortical neuronal damage than with 60 min 
of severe hypoglycemia (Figure 23A and Figure 20D).  Recurrent antecedent moderate 
hypoglycemia decreased cortical brain damage induced by 90 min of severe 
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hypoglycemia by 62% (RH-SH90: 1107 + 428 and CON-SH90: 2918 + 615 FJB+ cells, 
p<0.05).  Unlike hypoglycemia of shorter duration, 90 min of severe hypoglycemia also 
induced hippocampal brain damage (Figure 22 and Figure 23).  Recurrent antecedent 
hypoglycemia resulted in less hippocampal brain damage following 90 min of severe 
hypoglycemia compared to CON-SH90 (Figure 22 and Figure 23).  Specifically, RH-
SH90 had decreased FJB+ cells in the CA1 region by 74% (RH-SH90: 88+56 vs. CON-
SH90: 334+91 cell, p<0.05) and by 67% in the dentate gyrus (RH-SH90:274+119 vs. 
CON-SH90: 833 + 148, p<0.05) compared to CON-SH90 (Figure 23A).   
 Interestingly, recurrent hypoglycemia also reduced the episodes of seizure-like 
behavior observed during severe hypoglycemia (RH-SH90: 2.0±0.3 vs. CON-SH90: 
3.4±0.3, p<0.01) (Figure 23B).  There was a significant correlation between the number 
of episodes of seizure-like behavior and number of FJB+ cells (R=0.572, p< 0.05) 
(Figure 23C). 
In the absence of severe hypoglycemia, virtually no Fluoro-Jade positive cells 
(Fluoro-Jade B staining) nor pyknotic cells (H&E) were observed in the cortex and 
hippocampus of either the euglycemic CON-EUG or RH-EUG group (Figure 22 and 
Figure 23).  The lack of brain damaged cells indicated that the catheter implantation, 
recurrent moderate hypoglycemia, hyperinsulinemic clamp or glucose infusion per se 
does not cause significant brain damage.   
 
Preserved cognitive function in recurrently hypoglycemic rats.    
 Based on the extensive severe hypoglycemia induced damage noted in the cortex, 
including the sensorimotor cortex, locomotor activity and sensorimotor tests were 
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performed on the rats to evaluate whether severe hypoglycemia induced any detectable 
motor or sensorimotor deficits.  It was also important to assess the possible presence of 
sensorimotor deficits which could impede physical performance during the Morris maze 
testing and affect interpretation of spatial learning and memory results.  General activity, 
as measured by total ambulations, was not found to differ among the groups in terms of 
either total activity summed over the entire session, the response to novelty of the test 
field (i.e. block 1), or in the habituation of activity over time (Figure 24A). Two way 
ANOVA indicated that as a group, the severe hypoglycemic rats (both CON-SH90 and 
RH-SH90) exhibited significantly (p=0.02) more rearing than the two groups of EUG rats 
(Figure 24B).  Data from the walking initiation, ledge, platform, and 90
o
 incline tests 
were not significantly different between groups (Figure 24C-F).   
During the cue (Figure 25A) and place (Figure 25C) trials, the CON-SH90 rats 
performed very poorly compared to the other three groups in spite of having normal 
swimming speeds (Figure 25B, D).  The CON-SH90 group had significantly longer path 
lengths across the blocks of trials compared to the CON-EUG group (P=0.0002) 
documenting impaired performance as a result of the severe hypoglycemia. Other 
important comparisons showed that the RH-SH90 group had significantly shorter path 
lengths relative to the CON-SH90 group (P=0.0025), while no differences were observed 
between the RH-SH90 versus the CON-EUG group nor between the two EUG control 
groups. Analysis of the escape latency data (not shown) yielded essentially the same 
results.  
During the place (spatial learning) trials, the CON-SH90 rats again showed 
significant performance deficits, with the degree of impairment appearing to be even 
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greater than that observed during the cued condition.  Comparisons showed that the 
CON-SH90 group had significantly (P=0.0001) longer path lengths across the blocks of 
trials compared to the CON-EUG rats (Figure 25C).  Importantly, in rats that experienced 
severe hypoglycemia, prior recurrent moderate hypoglycemia improved performance as 
evidenced by significantly (p = 0.0006) shorter path lengths in the RH-SH90 versus the 
CON-SH90 group (Figure 25C).  Again, no differences were observed between the two 
euglycemic control groups. The same pattern of results was found for the escape latency 
(data not shown).   
The results of the probe trial (Figure 26A-C) mirrored the results obtained during 
the cue and place trials showing impaired memory retention due to severe hypoglycemia 
and a ―rescue‖ of this deficit with antecedent recurrent moderate hypoglycemia.  During 
the probe trial, CON-SH90 rats made significantly fewer platform crossings relative to 
the CON-EUG controls (P=0.014) (Figure 26A).  There were, however, no differences in 
platform crossings between the CON-SH90 and RH-SH90 rats.   With regard to spatial 
bias and average proximity to previous platform location, CON-SH90 did show an 
impaired performance and RH-SH90 demonstrated a completely normal performance.  In 
spatial bias analysis, pool quadrants times showed that the RH-SH90, CON-EUG, and 
RH-EUG groups all exhibited a spatial bias for the target quadrant whereby each group 
spent significantly more time in the target quadrant compared to the times spent in each 
of the other pool quadrants (P < 0.0025). Unlike the other groups, the CON-SH90 rats did 
not show a significant spatial bias for the target quadrant using these criteria (Figure 
26B).  The examination of average proximity to previous platform location, CON-SH90 
group demonstrated an impaired performance with a significantly higher average 
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proximity scores compared to the CON-EUG controls (P = 0.014) (Figure 26C). 
Importantly, RH-SH90 group had significantly lower average proximity scores compared 
to the CON-SH90 group (p = 0.014) and performed similarly relative to the CON-EUG 
controls.   In summary, during the probe trial, severe hypoglycemia (CON-SH90) 
significantly impaired all three tests of memory retention, and antecedent recurrent 
moderate hypoglycemia pretreatment (RH-SH90) significantly improved memory testing 
(indeed, completely prevented the severe hypoglycemia induced memory deficit) in 2 out 
of 3 tests.  
 Interestingly, the number of episodes of seizure-like behavior during severe 
hypoglycemia were positively correlated with place trial performance during Morris 
water maze testing (Figure 26D).  Specifically, increases in the number of episodes of 
seizure-like behavior were associated with longer average path lengths during the place 
trials (R=0.685, p<0.001) (Figure 26D).   
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Figure 19.  Experimental Protocol for induction of recurrent moderate 
hypoglycemia, induction of severe hypoglycemia, and behavioral testing.  Arterial 
and venous catheters were implanted into 9 week-old Sprague Dawley rats.  After one 
week of recovery, animals were either given an insulin injection for three consecutive 
days to induce moderate hypoglycemia (25-40 mg/dl) for three hours per day or they 
were given saline injections as a control.  On the fourth day, rats underwent a severe 
hypoglycemic (10-15 mg/dl) hyperinsulinemic (0.2 U/kg/min) clamp for either 60 or 90 
min, or alternatively, underwent a 90 min euglycemic (~80mg/dl) hyperinsulinemic (0.2 
U/kg/min) clamp.  Animals were either sacrificed one week later to assess neuronal 
damage by H&E and Fluoro-Jade B staining, or animals underwent sensorimotor and 
cognitive testing 6-8 weeks following the clamp. 
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Figure 20.  Recurrent Hypoglycemia attenuates brain damage after 60 minutes of 
severe hypoglycemia.    (A)  Blood glucose levels in rats subjected to a 60 minute severe 
hypoglycemic (SH) (10-15 mg/dl) hyperinsulinemic (0.2 U/kg/min) clamp.  Blood 
glucose was not significantly different between saline-treated (CON-SH60, , n=6) and 
recurrently hypoglycemic rats (RH-SH60, , n=10) during 60 minutes of severe 
hypoglycemia.  (B) Epinephrine levels were measured before the onset of severe 
hypoglycemia (basal) and 30 min into hypoglycemia.  No difference was observed during 
the basal period, and as expected, RH-SH60 rats (black bar) had an attenuated 
epinephrine response to hypoglycemia compared to CON-SH60 rats (white bar) (* p < 
0.05, by Student t-test).  (C) Representative hematoxylin and eosin (H&E) and Fluoro-
Jade B positive staining in the cortex of saline-treated (CON-SH60) and recurrently 
hypoglycemic (RH-SH60) rats one week following 60 min of severe hypoglycemia.  
Neuronal damage is indicated by pyknotic cells (H&E staining, green arrows) or with 
Fluoro-Jade B positive cells (green fluorescence).  Scale bar = 100 μm (D) Quantification 
of Fluoro-Jade B staining in CON-SH60 (white bar, n=6) and in RH-SH60 (black bar, 
n=10).  Following severe hypoglycemia, RH rats had significantly less degenerating cells 
in the cortex compared to CON rats (* p < 0.05, by Student t-test). 
81 
 
 
 
Figure 21.  Blood glucose and epinephrine response during 90 min of severe 
hypoglycemia. (A) Blood glucose was not significantly different between saline-treated 
(CON-SH90, , n=9) and recurrently hypoglycemic rats (RH-SH90, , n=8) during 90 
minutes of severe hypoglycemia.  Hyperinsulinemic euglycemic (~80 mg/dl) clamps 
were also performed in saline treated (CON-EUG, , n=9) and in recurrently 
hypoglycemic rats (RH-EUG, , n=11).  Blood glucoses were not significantly different 
between euglycemic groups.  (B) Epinephrine levels were measured before the onset of 
severe hypoglycemia (basal) and 30 min into hypoglycemia.  No difference was observed 
during the basal period, but RH-SH90 rats (black bar) had an attenuated epinephrine 
response to hypoglycemia compared to CON-SH90 (white bar) (* p<0.05). 
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Figure 22.  Recurrent hypoglycemia limits brain cell death one week following 90 
min of severe hypoglycemia.  (A) Representative hematoxylin and eosin staining of the 
cortex and hippocampal structures, CA1 and the dentate gyrus (DG), one week following 
90 minute severe hypoglycemic clamps or euglycemic clamps in recurrently 
hypoglycemic (RH-SH90 and RH-EUG, respectively) and saline injected rats (CON-
SH90 and CON-EUG). Rats that underwent severe hypoglycemia had damaged neurons 
characterized by pyknotic nuclei (green arrows) Scale bar = 100 μm  (B) Fluoro-Jade B 
positive cells (FJB+, green fluorescence) in the cortex, hippocampal CA1 region and 
dentate gyrus (DG).  Scale bar = 100 μm       
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Figure 23. Quantification of brain cell death following an episode of severe 
hypoglycemia and correlation to episodes of seizure-like behavior.   (A) Following 90 
minutes of severe hypoglycemia, the markedly increased number of FJB+ cells in the 
cortex, CA1, and dentate gyrus observed in the CON-SH90 (
SH - CON 
SH-RH 
Plot 1 Zero
SH - CON: -- 
SH - CON: -- 
SH-RH 
) was significantly 
(*p<0.05) reduced by antecedent recurrent moderate hypoglycemia (RH-SH90, ).  
White and black bars representing Fluoro-Jade B in CON-EUG and RH-EUG groups are 
not visible in this figure as no appreciable brain damage was observed in euglycemic 
control rats.  (B) Euglycemic rats (CON-EUG and RH-EUG) experienced no seizure-like 
behavior.  Rats exposed to 90 min severe hypoglycemia exhibited seizure-like behavior, 
although RH-SH90 ( ) had significantly less seizure-like behavior than CON-SH90 
(
SH - CON 
SH-RH 
Plot 1 Zero
SH - CON: -- 
SH - CON: -- 
SH-RH 
) (p<0.01).  (C) In rats that experienced severe hypoglycemia (RH-SH90 and CON-
SH90), seizure-like behaviors positively correlated with the amount of Fluoro-Jade B 
cells in the hippocampus (R=0.572, P<0.05).   
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Figure 24.  Locomotor activity and sensorimotor function 6-8 weeks following severe 
hypoglycemia or euglycemic clamp.  (A)  No significant differences were observed 
between groups in terms of ambulations (CON-EUG, , n=7; RH-EUG, , n=9; CON-
SH90, , n=11; RH-SH90, , n=9).  (B) The SH90 groups (CON-SH90, 
SH - CON 
SH-RH 
Plot 1 Zero
SH - CON: -- 
SH - CON: -- 
SH-RH 
, and 
RH-SH90, ) exhibited significantly (p = 0.017) more rearing than the EUG groups 
(CON-EUG,  and RH-EUG, ).  Sensorimotor function was also assessed by 
walking initiation task (C), ability to balance on a ledge (D), remain on a platform (E), or 
stay on a 90
o
 inclined screen (F).  Analyses conducted on the data from these 
sensorimotor tests showed no significant differences between groups tested. 
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Figure 25.  Antecedent recurrent hypoglycemia mitigated cognitive dysfunction 
induced by severe hypoglycemia as assessed by the cue and place trials during 
Morris water maze testing.  Morris water maze testing was performed 6-8 weeks 
following severe hypoglycemic or euglycemic clamps.  (A) During the cue trial, control 
rats exposed to 90 min of severe hypoglycemia (CON-SH90, , n=11) performed worse 
as evidenced by higher escape path lengths compared to euglycemic control (CON-EUG, 
, n=7) (
a
p=0.002).  Notably, rats exposed to recurrent moderate hypoglycemia before 
severe hypoglycemia (RH-SH90, , n=9) had shorter escape path lengths than CON-
SH90 (
b
p=0.0025)
 
and performed similarly to CON-EUG and RH-EUG ( , n=9).  (B)  
Swim speeds during the cue trials were similar between groups.  (C)  During the place 
trials, CON-SH90 had significantly higher escape path lengths compared to CON-EUG 
(
c
p=0.0001) and RH-SH90 (
d
p=0.0006).  (D) In the place trials, swim speeds were similar 
between groups.    
a 
P<0.01 vs. CON-EUG, 
b
 P<0.01 vs. RH-EUG, 
c
 P <0.01 vs. RH-
SH90.  All statistical analyses by ANOVA.   
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Figure 26.  Antecedent recurrent hypoglycemia limited cognitive impairments 
induced by severe hypoglycemia as assessed during the probe trials of Morris water 
maze testing.  (A)  CON-SH90 (
SH - CON 
SH-RH 
Plot 1 Zero
SH - CON: -- 
SH - CON: -- 
SH-RH 
)had significantly less platform crossings than 
CON-EUG ( ) (
e
p=0.014)
 
.  No significant difference was observed between CON-
SH90 and RH-SH90 ( ) nor between CON-EUG and RH-EUG ( ).  (B) RH-
SH90, CON-EUG, and RH-EUG had a spatial bias towards the target quadrant while 
CON-SH90 did not (
*
p<0.0025).  (C)  During the probe trial, CON-SH90 rats showed an 
average proximity to the platform location that was significantly farther away than that of 
the CON-EUG (
f
p=0.014).  RH-SH90 rats swam significantly closer to the platform 
location than CON-SH90 (
g
p=0.014), similar to euglycemic controls.  (D) The number 
episodes of seizure-like behaviors observed during severe hypoglycemia 6-8 weeks prior 
positively correlated with average path length during the place trials (R=0.685, P<0.001, 
n=20). 
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DISCUSSION 
Since severe hypoglycemia affects 40% of insulin treated people with diabetes 
(136), concern regarding the hazardous potential for severe hypoglycemia to cause ―brain 
damage‖ continues to be a very real barrier for patients to fully realize the benefits 
associated with intensive glycemic control (137).  An area of intense controversy is the 
extent to which severe hypoglycemia causes neuronal damage and cognitive dysfunction.  
Animal models have unambiguously demonstrated that acute severe hypoglycemia 
(blood glucose <18 mg/dl) induces neuronal damage and subsequent deficits in learning 
and memory associated with severe hypoglycemia-induced neuronal damage (53;54;130).  
Due to the retrospective nature of clinical studies investigating severe hypoglycemia 
induced brain damage, a direct link between severe hypoglycemia and cognitive deficits 
has been less well established.  Many studies have shown that episodes of severe 
hypoglycemia alters brain structure (64;131) and causes significant cognitive damage 
(56-66) yet other studies fail to show such an association (67-72).  In the real world 
clinical setting, the extent of antecedent glycemic control (including recurrent 
hypoglycemia) could be a critical factor in explaining differences between animal and 
clinical studies and may partially explain the variable results from clinical trials.  Patients 
with the highest incidence of severe hypoglycemia are those who maintain intensive 
glycemic control, and hence are likely to have had recurrent bouts of moderate 
hypoglycemia. In this study, it was observed that recurrent moderate hypoglycemia 
―preconditioned‖ the brain and protected it against brain damage and cognitive 
dysfunction induced by a subsequent episode of severe hypoglycemia. 
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In these experiments, severe hypoglycemic brain injury was consistently induced 
with hyperinsulinemic hypoglycemic clamps designed to carefully control the depth and 
duration of severe hypoglycemia.  The dose of administered insulin was pharmacological 
by experimental design and was necessary to overcome the intact counterregulatory 
response present in non-diabetic rats and maintain glycemia in the 10-15 mg/dl range.  
The total insulin dose of 20-35 U/kg is consistent with doses used in other hypoglycemic 
rodent studies (54;138-142).  The clamps were performed in awake animals in order to 
avoid the confounding effects of anesthesia (143-146).  Profound neuronal damage was 
observed in rats that experienced an episode of severe hypoglycemia (blood glucose < 15 
mg/dl).  Severe hypoglycemia of 60 minute duration resulted in brain damage only in the 
cortex.  90 minutes of severe hypoglycemia resulted in 6-fold more cortical neuronal 
damage compared to 60 minutes of severe hypoglycemia.  Further, 90 minutes of severe 
hypoglycemia resulted in significant damage in the hippocampus, an area important for 
learning and memory.  These studies demonstrate that rats exposed to three days of 
recurrent, moderate hypoglycemia, had less severe hypoglycemic brain injury in both the 
cortex and hippocampus.  Thus, as with ischemic preconditioning (76), hypoglycemic 
preconditioning attenuated brain damage by 62-74%.  Although hypoglycemia-induced 
neuronal damage in the hypothalamus has been noted (147), other reports did not note 
damage to the hypothalamus (148), and in this study no hypoglycemia induced neuronal 
injury to the hypothalamus was observed. 
It was important to assess whether the beneficial histopathological findings of 
reduced neuronal damage in recurrently, moderately hypoglycemic rats were associated 
with improved behavioral and cognitive performance.  Consistent with other protocol 
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designs (53;54;140), histopathological outcomes were assessed one week following the 
hypoglycemic neuronal insult and cognitive studies were performed 6-8 weeks later in a 
separate group of similarly treated rats.  This later assessment of cognitive damage has 
been shown to be a more useful measure of clinical outcome as well as a better functional 
index of neuroprotection because it allows for a more complete and integrated evaluation 
of ongoing damage and/or possible recovery (149).  As compared to the extensive brain 
damage in rats exposed to severe hypoglycemia, it was hypothesized that the reduced 
neuronal damage in recurrently hypoglycemic rats would be associated with improved 
performance on several behavioral and cognitive indices.  
The results of the 1-h locomotor activity test and series of sensorimotor measures 
suggested that the rats had no meaningful deficit in sensorimotor function resulting from 
severe hypoglycemia.  These results imply that all groups were generally healthy and not 
suffering from residual malaise associated with the severe hypoglycemia. Interestingly, 
the rats subjected to the severe hypoglycemia reared significantly more often than the 
euglycemic controls which likely reflects possible changes in emotionality or information 
processing rather than sensorimotor disturbances and shows, importantly, that the severe 
hypoglycemia did not induce gross hindlimb dysfunction. Further, no differences were 
observed among the four groups in sensorimotor tests (Figure 24) or in swimming speeds 
during the cued and place trials (Figure 25).   In summary, the data from the activity tests, 
sensorimotor measures, and swim speeds all indicate the rats exposed to the severe 
hypoglycemia were generally healthy at the beginning of behavioral testing and showed 
no signs of a sensorimotor impairment which could have affected interpretation of 
cognitive function testing as measured during in the Morris Water maze.      
90 
 
Cognitive testing results obtained during the water maze testing documented 
severe acquisition performance deficits in the CON-SH90 rats during the cued and place 
conditions, and that these impairments were prevented by the antecedent recurrent 
moderate hypoglycemic treatment. Specifically, analysis of the escape path length and 
latency data showed that the CON-SH90 rats were significantly impaired relative to the 
CON-EUG controls during both the cued and place trials, and that the RH-SH90 group 
performed significantly better than the CON-SH90 rats during both conditions.   
There were three tests of memory performance evaluated with the probe trial 
(Figure 26).  With regard to platform crossings, severe hypoglycemia induced a 
significant impairment in rats exposed to severe hypoglycemia.  Recurrent hypoglycemia 
tended to improved performance but was not significant (RH-SH90 vs CON-SH90) 
indicating that the recurrent hypoglycemia was not able to completely reverse the 
retention deficits concerning the exact location of the platform.  However, analysis of the 
spatial bias and average proximity data indicates that recurrent hypoglycemia did 
preserve the memory of a more generalized platform location. Specifically, the two 
euglycemic control groups each showed a significant spatial bias for the target quadrant 
that had contained the submerged platform while the CON-SH90 rats showed no such 
bias indicating a cognitive impairment in spatial bias induced by severe hypoglycemia. 
The RH-SH90 rats also showed a significant spatial bias for the target quadrant indicating 
that recurrent hypoglycemia treatment completely restored spatial bias.  Assessment of 
average proximity again showed a cognitive impairment due to severe hypoglycemia as 
the CON-SH90 group had an average proximity that was farther away from the platform 
location than that of the CON-EUG and RH-SH90 rats.  Since the average proximity 
91 
 
values for the RH-SH90 and CON-EUG groups were not different, recurrent 
hypoglycemia treatment fully reversed this cognitive deficit induced by severe 
hypoglycemia.  These findings indicate that memory retention performance was impaired 
in the CON-SH90 rats relative to the CON-EUG controls on all probe trial variables, and 
recurrent hypoglycemia prevented impairments on 2/3 probe trials indices. 
Since the CON-SH90 rats exhibited significant performance deficits during the 
cued trials, it is not possible to know whether the impaired place trials performance was 
due to compromised spatial learning and memory processing or to non-associative 
disturbances, or to both types of functional deficits. Reasons for the poor cued trials 
performance could include impairments in visual function, alterations in motivation, or a 
global decrement in generalized cognitive functioning which would encompass simple 
cued learning as well as more complex spatial learning and memory capabilities. 
Importantly, the profound cognitive defects induced by severe hypoglycemia in both cued 
learning deficits and compromised spatial learning and memory processing were 
prevented by antecedent recurrent moderate hypoglycemia.  
Consistent with the notion that recurrent hypoglycemia induces an adaptive brain 
response is the observation that recurrent hypoglycemic rats had less seizure-like 
behavior during severe hypoglycemia (Figure 23), indicating the RH treated brain was 
better able to tolerate severe hypoglycemia.  Consistent with previous studies from the 
laboratory (132), the degree of neuronal damage induced by severe hypoglycemia was 
correlated with the number of episodes of seizure-like behavior.  Novel findings are now 
presented indicating that the number of episodes of seizure-like behavior observed during 
severe hypoglycemia was also correlated with cognitive performance.  These 
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correlations, however, do not imply causality.  In the setting of profound hypoglycemia, 
vulnerable brain regions may be susceptible to both damage and seizure activity.  As in 
the real world setting, witnessed hypoglycemic seizures were defined clinically.  In the 
absence of electroencephalogram (EEG) monitoring, the effect of subclinical seizures 
(i.e. seizures not associated with noticeable motor activity) on brain damage and 
cognition could not be assessed.  Nonetheless, observable instances of seizure-like 
behavior correlated with the extent of neuronal damage and long-term cognitive function, 
and thus, can be used as a marker for neuronal injury and is prognostic of long-term 
cognitive outcomes.  Indeed, clinical studies support these finding because more than 
severe hypoglycemia per se, the presence of hypoglycemic seizures correlate more 
closely with impaired cognitive function (59;65).   
The amount and distribution of severe hypoglycemia induced neuronal damage 
was markedly different between the 60 minute and 90 minute clamp studies (Figure 20 
and Figure 23).  In spite of similar degrees of hypoglycemia (10-15 mg/dl) the extra 30 
minutes of severe hypoglycemia induced a 6-fold increase in cortical brain damage and 
markedly increase hippocampal brain damage (which was minimal in the 60 minute 
clamp).  These findings emphasize the importance of the duration of severe 
hypoglycemia, and not hypoglycemic nadir alone, as a critically important component in 
determining the extent of brain damage (53).  Unlike noting the presences or absence of 
seizures, noting the duration of severe hypoglycemia is impractical to estimate clinically 
and, thus, unlike seizure activity would not be a clinically useful marker for neuronal 
damage.  Interestingly though, the likely variability of severe hypoglycemia duration in 
the clinical situation could be another important factor contributing to the variable 
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amounts of cognitive impairments noted in the clinical literature.  Given the variability in 
the extent of clinical symptoms associated with severe hypoglycemia, it is not surprising 
that there exists a marked variability in the reported neurological consequences of severe 
hypoglycemia in retrospective clinical reports. 
Independent of episodes of severe hypoglycemia, previous studies have shown 
that recurrent moderate hypoglycemia can alter cognitive function.  In one study, 
recurrent moderate hypoglycemia did not cause neuronal damage in the hippocampus (as 
confirmed in this study) but did impair hippocampal long-term potentiation (LTP), a 
cellular mechanism believed to be involved in learning and memory (150).  The impaired 
LTP after recurrent hypoglycemia suggests that RH would lead to impaired cognitive 
function.  Other studies showed an opposite effect in that antecedent hypoglycemia 
improved cognitive ability in rats tested in an euglycemic state (151;152).  In the current 
study of euglycemic control rats that were not exposed to severe hypoglycemia, no 
detrimental or beneficial effect of recurrent hypoglycemia on cognitive ability was 
observed during the Morris water maze testing.   This discrepancy between studies is 
likely due to the later point in time when cognition was tested.  In the current study, 
cognitive ability was tested 6-8 weeks after the recurrent moderate hypoglycemia.  LTP 
was measured a few days after recurrent hypoglycemia and normal LTP function may 
have recovered if LTP was measured at a later time point.  Further, in studies that showed 
a beneficial cognitive effect of RH, cognition was measured a day following RH.  Again, 
any changes brought about by RH alone in this study may have evanesced during a 6-8 
week recovery period.  Indeed, since 2-3 weeks of scrupulous avoidance of hypoglycemia 
negates the adaptive deficit in sympathoadrenal response associated with recurrent 
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hypoglycemia (153;154), any such adaptive effect of antecedent hypoglycemia on 
cognition would likely have dissipated after 6-8 weeks in euglycemic controls. 
Although recurrent moderate hypoglycemia has repeatedly been shown to lead to 
maladaptive responses resulting in hypoglycemia unawareness and hypoglycemia 
associated autonomic failure (HAAF), the mechanism(s) by which recurrent 
hypoglycemia leads to these adaptations remain elusive.  Similarly, the current 
experiments do not identify the mechanisms by which recurrent moderate hypoglycemia 
affords, [1] protection against hypoglycemia induced neuronal damage, [2] limitation to 
hypoglycemia induced neurocognitive dysfunction, and [3] increased thresholds for 
hypoglycemic seizures.  Putative mechanisms for these beneficial adaptations could 
include glycogen supercompensation—increased brain glycogen content above pre-
hypoglycemic levels (155-159).  By keeping a higher level of stored fuel units, increased 
brain glycogen content has been shown to reduce hypoglycemic neuronal injury by 
maintaining brain electrical activity and forestalling EEG isoelectricity (4).  Enhanced 
nutrient transport may also contribute to the neuroprotective effects of recurrent 
hypoglycemia (160;161)  Monocarboxylate acid transport is increased during 
hypoglycemia in patients with well-controlled type I diabetes (160;161).  Increase 
transport of monocarboxylate acids (e.g. lactate) could provide an alternative source of 
energy and maintain neuronal function (54).  Several other possibilities could account for 
the neuroprotective effect such as alterations in brain metabolism or neuronal activity 
(155;162-165).  Recurrent hypoglycemia has been shown to enhance the inhibitory 
neurotransmitter, GABA, which could reduce neuronal activity and limit excitotoxic 
damage (163).  Further studies on the precise mechanisms of how recurrent 
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hypoglycemia exerts its neuroprotective effects to subsequent severe hypoglycemia are 
warranted. 
These studies demonstrate that recurrent moderate hypoglycemia preconditions 
and protects the brain against severe hypoglycemia induced neuronal damage and its 
associated cognitive deficits.  These intriguing findings suggest that recurrent bouts of 
moderate hypoglycemia that occur with intensive glycemic control might, paradoxically, 
render an individual more prone to, but less vulnerable to, an episode of severe 
hypoglycemia.  If the current data indicating a neuroprotective preconditioning effect of 
recurrent moderate hypoglycemia were to be extrapolated to the clinical setting, it could 
explain the apparent divergent findings between animal and clinical studies and may also 
explain the seemingly incongruous clinical findings that intensively treated patients who 
experience recurrent moderate and severe hypoglycemia may be paradoxically protected 
from severe hypoglycemia induced brain damage and (fortunately) may not suffer from 
associated long-term cognitive damage (70;166). 
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THESIS DISCUSSION 
The major pathophysiological defects responsible for the development of type 2 diabetes 
have traditionally been attributed to insulin resistance in muscle and the liver and β-cell 
failure.  However, recent research has found other organs that are involved in the 
pathogenesis of diabetes such as adipose tissue, the gastrointestinal tract, the pancreatic 
α-cell, and the kidneys (167).  Of particular interest, the brain has also been implicated in 
contributing to the development of diabetes.  The brain receives afferent neuronal and 
hormonal signals from the rest of the body and integrates these signals in order to elicit 
an appropriate response to maintain whole body energy homeostasis.  Independent of 
these neuronal and hormonal signals, the brain can also directly sense nutrients, 
particularly glucose, and direct efferent signals to regulate glucose homeostasis.  
Disruption of the ability of the brain to sense glucose results in impaired glucose 
tolerance, a hallmark in the progression to diabetes (19).  Additionally, impaired neuronal 
glucose sensing may also increase the risk of developing severe hypoglycemia, a 
common complication associated with tight glycemic control that occurs with intensive 
insulin therapy.  As diabetes is characterized by disrupted energy homeostasis leading to 
hyperglycemia, glycemic management requires a careful balance between lowering 
glucose towards normal while avoiding hypoglycemia.  Understanding the mechanisms 
in which the brain senses and responds to glucose to prevent hyperglycemia as well as 
hypoglycemia is of great importance to reducing the risk and improving the management 
of diabetes.  The work of this thesis found important roles of neuronal GLUT4 and the 
hexosamine biosynthetic pathway (HBP) in the hypothalamus in the regulation of 
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peripheral insulin sensitivity and whole body energy homeostasis.  Further, neuronal 
GLUT4 was found to be important in the counterregulatory response to hypoglycemia 
while antecedent hypoglycemia was found to precondition and protect the brain from 
severe hypoglycemia-induced neuronal damage.   
 
Insulin Signaling and Neuronal Glucose Sensing 
Insulin’s role in the regulation of energy homeostasis has been extensively studied in 
peripheral tissues.  Insulin inhibits hepatic glucose production and stimulates glucose 
uptake into skeletal muscle and adipose tissue in order to lower blood glucose.  However, 
insulin has also been shown to act centrally to modulate brain glucose sensing and whole 
body energy homeostasis.  One of the first studies demonstrating a role for insulin action 
in the brain revealed that infusion of insulin into the third cerebral ventricle of primates 
decreases food intake and body weight (126).  Subsequent studies supported these 
findings and found more extensive functions of central insulin signaling.  For example, 
infusion of insulin into the third cerebral ventricle suppresses hepatic glucose production 
(119).  Studies involving genetic deletion of neuronal insulin receptors further underscore 
the importance of brain insulin action in the regulation of energy and glucose 
homeostasis.  Knock-out of neuronal insulin receptors or knock down of hypothalamic 
insulin receptors results in hyperphagia, peripheral insulin resistance, and impaired 
glucose tolerance (36;37).  Further, neuronal insulin signaling is required for eliciting a 
full counterregulatory response to hypoglycemia (38).  Thus, identification of factors that 
modulate central insulin signaling may also be important in regulating energy and 
glucose homeostasis.  GLUT4 is the major effector protein for insulin stimulated glucose 
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uptake.  Deletion of GLUT4 in skeletal muscle or adipose tissue results in insulin 
resistance (26-28).  Additionally, excess nutrients such as hyperglycemia have a negative 
impact on insulin signaling.  Hyperglycemia reduces insulin stimulated glucose uptake, 
and this effect has been shown to be mediated by increased metabolism through the 
hexosamine biosynthetic pathway (42;48;113).  As GLUT4 and hyperglycemia affect 
insulin signaling peripherally, this thesis observed important functions of GLUT4 and 
hyperglycemia in the central nervous system in modulating energy homeostasis. 
 
Brain Glucose Transporter 4 
 To delineate the roles of GLUT4 in the brain, neuronal specific GLUT4 knockout 
mice (NG4KO) were created.  Tissue specific deletion of neuronal GLUT4 did not affect 
body weight or fat pad mass.  Further, neuronal GLUT4 did not have an effect on basal 
glucose homeostasis as fasting and fed glucose levels were similar in NG4KO mice 
compared to littermate controls.  Interestingly, neuronal GLUT4 did have an important 
role in glucose homeostasis in response to a glucose load.  Intraperitoneal glucose 
tolerance tests revealed impaired glucose tolerance in NG4KO mice compared to 
littermate controls. To directly assess insulin sensitivity, hyperinsulinemic-euglycemic 
clamps were performed.  Neuronal GLUT4 deletion was found to result in whole body 
insulin resistance as NG4KO mice required a significantly lower glucose infusion rate to 
maintain euglycemia than littermate controls.  The insulin resistance was not caused by 
changes in insulin stimulated glucose uptake in peripheral tissues because glucose uptake 
in skeletal muscle and adipose tissue were not different between NG4KO mice and their 
respective littermate controls.  Instead, hepatic insulin resistance was responsible for the 
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lower glucose infusion rate and reduced insulin sensitivity seen in NG4KO mice.  The 
ability of insulin to suppress hepatic glucose production (HGP) was significantly 
impaired in NG4KO mice.  Interestingly, brain insulin signaling is also critical for 
insulin’s ability to fully suppress HGP (98;99).  It is feasible that the altered hepatic 
insulin sensitivity in NG4KO mice may be a result of the requirement for neuronal 
GLUT4 in exerting insulin’s effects in the CNS.  The absence of neuronal GLUT4 may 
prevent insulin action in the brain from exerting its effects on HGP.  More direct studies 
to understand this relationship between central GLUT4 and insulin are warranted.  
Nonetheless, these studies found a novel role of brain GLUT4 in the regulation of insulin 
sensitivity, glucose tolerance, and hepatic glucose production. 
 
Hexosamine Biosynthetic Pathway and Hypothalamic Protein Glycosylation 
Nutrient excess in the setting of hyperglycemia increases flux through the 
hexosamine biosynthetic pathway leading to increased O-linked protein glycosylation.   
Increased protein glycosylation has been implicated as a mechanism by which 
hyperglycemia induces insulin resistance in adipose tissue and skeletal muscle.  Whether 
these same processes also occur in the central nervous system to modulate central insulin 
sensitivity and, subsequently, energy homeostasis were investigated.  The hypothesis that 
chronic infusion of glucose or glucosamine, a molecule that directly enters the HBP, into 
the hypothalamus would induce central insulin resistance leading to increased food intake 
and excessive body weight gain was tested.   
Contrary to the original hypothesis, hypothalamic glucose infusion reduced body 
weight.  Hypothalamic glucose concentrations may have not reached a level sufficient 
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enough to induce hypothalamic insulin resistance.  As the brain is highly metabolically 
active, the infused glucose may have been simply utilized by the brain.  Indeed, a 
previous study demonstrated a 7 day infusion of glucose into the third ventricle decreased 
body weight (8).  In peripheral tissues, the hyperglycemia mimetic glucosamine is a more 
potent inducer of UDP-GlcNAc production (168) and, subsequently, insulin resistance 
(40;41;48).  Glucosamine directly enters the hexosamine biosynthetic pathway (HBP) to 
increase protein glycosylation and consequently induces insulin resistance in peripheral 
tissues (40;41;48). Therefore, glucosamine was infused into the mediobasal 
hypothalamus and the effects on energy homeostasis were investigated.   
As with hypothalamic glucose infusion, hypothalamic glucosamine infusion 
reduced body weight and additionally reduced food intake.  Hypothalamic glucosamine 
infusion also resulted in the expected increase in overall O-linked protein glycosylation 
(Figure 16).  Interestingly, the degree of hypothalamic protein glycosylation was 
significantly and inversely correlated to the degree of weight gain.  That is, increased 
protein glycosylation correlated with lower the weight gain and vice versa (Figure 16).  
Further, the anorexigenic effects of hypothalamic glucosamine infusion could be 
attributed to its effects on central insulin signaling.  Mediobasal hypothalamic infusion of 
glucosamine enhanced hypothalamic insulin sensitivity, and insulin is known to have 
anorexigenic effects centrally (124-126).  Thus, the hexosamine biosynthetic pathway 
and the degree of protein glycosylation were important processes in the regulation of 
whole body energy homeostasis and insulin sensitivity centrally and peripherally.   
Systemic glucose and insulin levels were not affected by hypothalamic 
glucosamine infusion.  However, insulin tolerance tests did demonstrate that the 
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glucosamine treated rats were more insulin sensitive than controls (Figure 17).  The 
reduced body weight in the glucosamine infused animals (Figure 15) could account for 
the improved peripheral insulin sensitivity, but the enhanced hypothalamic insulin 
sensitivity (Figure 17) may have also contributed to the improved peripheral insulin 
sensitivity (36;37). 
These data provide evidence of a novel nutrient sensing system in the 
hypothalamus.  Enhanced metabolism through the HBP may increase O-GlcNAc, which 
in turn, reduces food intake, limits body weight gain, and improves both central and 
peripheral insulin sensitivity.  The HBP may become a potential therapeutic target to 
modulate food intake and body weight and, hence, combat the ever-growing epidemic of 
obesity and diabetes.   
 
This thesis work demonstrated a role for both neuronal GLUT4 and hypothalamic HBP in 
modulating peripheral insulin sensitivity.  As peripheral insulin resistance is a hallmark in 
the development of type 2 diabetes, both neuronal GLUT4 and the HBP may be potential 
therapeutic targets to combat type 2 diabetes.   
 
Hypoglycemia 
 Intensive insulin therapy that lowers blood glucose towards normal reduces the 
long-term microvascular complications due to diabetes.  However, insulin replacement is 
an imperfect process that often results in relative insulin excess and repeated episodes of 
hypoglycemia.  Moderate hypoglycemia can acutely affect cognitive capabilities while 
more severe hypoglycemia can lead to seizures, coma, and even death.  For patients who 
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manage their diabetes with insulin therapy, hypoglycemia is the major obstacle in 
achieving tight glycemic control.  Thus, discovering mechanisms involved in preventing 
hypoglycemia as well as identifying ways to reduced brain injury due to severe 
hypoglycemia will have direct clinical impact for patients living with diabetes.  This 
thesis work found a novel and important role of neuronal GLUT4 in producing a full 
counterregulatory response to hypoglycemia.  Further, the studies of this thesis found a 
novel mechanism in neuroprotection, hypoglycemic preconditioning. 
 As brain insulin signaling is important in the counterregulatory response to 
hypoglycemia (CRR), the CRR was assessed NG4KO mice.  Genetic deletion of central 
GLUT4 resulted in impaired epinephrine and glucagon responses to hypoglycemia.     
Further, pharmacologic inhibition of brain GLUT4 also reduced both the epinephrine and 
glucagon response to hypoglycemia.   Interestingly, streptozotocin diabetic rats that have 
reduced GLUT4 expression in the brain (34) also have impaired epinephrine and 
glucagon responses to hypoglycemia (100;101).  These findings suggest intact brain 
GLUT4 function is necessary for producing a full CRR and further support the notion 
that brain GLUT4 is important in the modulation of neuronal glucose sensing.  Thus, 
brain GLUT4 may be a therapeutic target for the prevention of hypoglycemia. 
 If the counterregulatory response is inadequate to correct hypoglycemia, blood 
sugars may continue to fall leading to severe hypoglycemia.  Severe hypoglycemia can 
cause brain injury and encephalopathy (4;55;169).  Therefore, discovering ways to 
protect the brain from hypoglycemic brain injury is very important for patients who rely 
on insulin therapy and are at risk for experiencing severe hypoglycemia.  One potential 
mechanism for preventing severe hypoglycemia induced brain damage is via 
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preconditioning.  In other forms of stress such as ischemia, brief, mild episodes of 
ischemia will protect the brain from a subsequent, more severe ischemic episode.  These 
adaptive and protective changes in the brain to a moderate stressful stimulus are termed 
preconditioning.  This thesis work investigated whether moderate episodes of antecedent 
hypoglycemia may also precondition and protect the brain against a subsequent episode 
of more severe hypoglycemia. 
 These studies found that antecedent hypoglycemia was able to protect the brain 
from neuronal damage induced by a subsequent episode of severe hypoglycemia.  
Intriguingly, the number of seizure-like behaviors observed during the episode of severe 
hypoglycemia was also significantly reduced in rats that were pretreated with three days 
of antecedent, moderate hypoglycemia.  These data suggest that antecedent, moderate 
hypoglycemia induces adaptive changes within the brain that allows the brain to protect 
and better tolerate low blood sugars.  Further, these reductions in brain injury were 
associated with long-term preservation of cognitive function.  Six weeks after the severe 
hypoglycemia, rats that were pretreated with three days of antecedent recurrent 
hypoglycemia had significantly better spatial learning ability and memory.  Taken 
together, antecedent, moderate hypoglycemia did precondition the brain and protected it 
against severe hypoglycemia induced brain injury and cognitive dysfunction.   
Several results from the investigations on hypoglycemic preconditioning have 
direct clinical implications and corollaries.  First, the degree of neuronal damage and 
extent of cognitive impairments were strongly correlated with the number of episodes of 
seizure-like behaviors.  Rats that experienced greater number of seizure-like behaviors 
had more neuronal injury.  Further, rats that experienced more instances of seizure-like 
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behaviors during severe hypoglycemia also had more extensive long-term impairments in 
cognitive ability when spatial learning and memory were tested six weeks after the severe 
hypoglycemia.  Thus, episodes of seizure-like behaviors during severe hypoglycemia 
may be markers of neuronal injury and may be prognostic of long-term cognitive 
outcomes.  Indeed, clinical studies show that the presence of seizures during 
hypoglycemia correlate with impaired cognitive function (59;65). 
Hypoglycemia is a major complication with insulin therapy.  This thesis identified 
potential neuronal mechanisms that may prevent hypoglycemia as well as protect the 
brain against the deleterious effects of severe hypoglycemia.  Specifically, neuronal 
GLUT4 is essential for eliciting a full epinephrine and glucagon response to 
hypoglycemia, and antecedent hypoglycemia can precondition the brain and protect it 
against the hypoglycemic brain injury. 
 
Summary 
Central to both the pathogenesis and treatment of diabetes is the regulation of glucose 
homeostasis.  Dysfunction in glucose homeostasis such as insulin resistance and impaired 
glucose tolerance are the core pathophysiological processes involved in development of 
diabetes.  The inability of the body to adequately prevent hypoglycemia during intensive 
glycemic control in patients living with diabetes is the major obstacle in the management 
of diabetes.  The experiments in this thesis identified processes involved in brain glucose 
sensing/metabolism that are important in modulating central and peripheral insulin 
resistance, in preventing the occurrence of hypoglycemia, and in promoting neuronal 
viability.  Particularly, brain GLUT4 and hypothalamic HBP both were found to 
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modulate peripheral insulin sensitivity, and hence, are potential therapeutic targets for 
improving insulin sensitivity.  Further, brain GLUT4 was found to be a critical regulator 
of the counterregulatory response to hypoglycemia, thus is a potential therapeutic target 
for preventing the hypoglycemia that often occurs with insulin therapy.  Finally, 
antecedent hypoglycemia preconditions and protects the brain against severe 
hypoglycemia-induced injury and cognitive function, a mechanism that may explain why 
individuals who experience both moderate and severe hypoglycemia may, fortunately, 
not suffer from long term cognitive dysfunction associated with severe hypoglycemia. 
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